{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Headshot Cowan.jpg|frameless|upright=0.3|center]]
|<big>[[User:Andrewc072|Andrew J. Cowan, MD]]<br>Seattle Cancer Care Alliance<br>Seattle, WA</big><br>[https://www.linkedin.com/in/andrew-cowan-63b3a130/ LinkedIn]
|-
|}
''Are you looking for a regimen but can't find it here? It is possible that we've moved it to the [[Multiple_myeloma_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''.
<br><big>'''Note: due to its size/complexity, the multiple myeloma page has been split into three sub-pages:'''
*Induction (transplant eligible and ineligible) [''this page'']
*[[Multiple_myeloma,_consolidation_and_maintenance|First-line consolidation and maintenance]]
*[[Multiple_myeloma,_relapsed/refractory|Relapsed/refractory, including subsequent consolidation and maintenance]]
</big>
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}
{{#lst:Multiple myeloma|guidelines}}
<section begin=1st-line />
=First-line therapy (including transplant ineligible), randomized data=
''Note: most but not all multiple myeloma first-line regimens specify whether patients are transplant eligible, or not. The top-line inclusion criteria from each prospectively enrolling regimen are reported.''

==Bortezomib & Dexamethasone {{#subobject:b2104f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BD: '''<u>B</u>'''ortezomib, '''<u>D</u>'''examethasone
<br>Bd: '''<u>B</u>'''ortezomib, low-dose '''<u>d</u>'''examethasone
<br>Bort-Dex: '''<u>Bort</u>'''ezomib, '''<u>Dex</u>'''amethasone
<br>Vd: '''<u>V</u>'''elcade (Bortezomib), low-dose '''<u>d</u>'''examethasone
<br>VD: '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone

===Variant #1 {{#subobject:59cfe6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/33/33/3921.long Niesvizky et al. 2015 (UPFRONT)]
|rowspan=2 style="background-color:#1a9851"|Phase IIIb (E)
|1. [[#VMP|VMP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#VTD|VTD]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}

''This regimen was meant for transplant ineligible patients.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 4: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
**Cycles 5 to 8: 20 mg PO once per day on days 1, 2, 4, 5

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Bortezomib_monotherapy|Bortezomib consolidation]]

===Variant #2 {{#subobject:6a8cb5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/118/22/5752.full Moreau et al. 2011 (IFM 2007-02)]
|style="background-color:#1a9851"|Phase III (C)
|[[#VTD|vtD]]
|style="background-color:#d73027"|Inferior VGPR rate
|-
|}
''This regimen was intended for patients aged 65 years or younger with untreated symptomatic MM with measurable paraprotein in serum (greater than 1 g/dL) or urine (greater than 0.2 g/24 hours).''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 & 2: 40 mg (route not specified) once per day on days 1 to 4, 9 to 12
**Cycles 3 & 4: 40 mg (route not specified) once per day on days 1 to 4

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan, then autologous hematopoietic cell transplant]]

===Variant #3 {{#subobject:9d60fb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/28/30/4621.long Harousseau et al. 2010 (IFM 2005-01)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#VAD|VAD]]
|style="background-color:#d9ef8b"|Might have superior PFS
|-
|}
''This regimen was intended for patients age less than or equal to 65 years with untreated symptomatic MM with measurable paraprotein in serum (greater than 1 g/dL) or urine (greater than 0.2 g/24 h).''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 & 2: 40 mg PO once per day on days 1 to 4, 9 to 12 
**Cycles 3 & 4: 40 mg PO once per day on days 1 to 4

====Supportive medications====
*One of the following bisphosphonates recommended:
**[[Pamidronate (Aredia)]] 90 mg IV once every 4 weeks until first transplant
**[[Zoledronic acid (Zometa)]] 4 mg IV once every 4 weeks until first transplant
*"Antibiotics, antifungal agents, and antiviral prophylaxis in accordance with local practice."

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#DCEP|DCEP consolidation]] versus [[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|high-dose melphalan with autologous hematopoietic cell transplant]]

===Variant #4, weekly bortezomib {{#subobject:5f56bd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13243/full Girnius et al. 2014 (X05153)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.6 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23

'''35-day cycle for up to 6 cycles based on response and tolerance of side effects'''

===References===
<!-- Presented at the 48th Annual Meeting of the American Society of Hematology (ASH), December 9-12, 2006, Orlando, FL; the 49th Annual Meeting of the ASH, December 8-11, 2007, Atlanta, GA; the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30-June 3, 2008, Chicago, IL; and the 2008 Annual Meeting of the American Society of Hematology ASH/ASCO Joint Symposium, December 7, 2008, San Francisco, CA. -->
# '''IFM 2005-01:''' Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010 Oct 20;28(30):4621-9. Epub 2010 Sep 7. [http://jco.ascopubs.org/content/28/30/4621.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20823406 PubMed]
## '''Subgroup analysis:''' Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guérin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa AM, Hulin C, Facon T, Attal M, Minvielle S, Harousseau JL. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010 Oct 20;28(30):4630-4. Epub 2010 Jul 19. [http://jco.ascopubs.org/content/28/30/4630.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20644101 PubMed]
# '''IFM 2007-02:''' Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011 Nov 24;118(22):5752-8. Epub 2011 Aug 17. [http://www.bloodjournal.org/content/118/22/5752.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21849487 PubMed]
# '''X05153:''' Girnius SK, Lee S, Kambhampati S, Rose MG, Mohiuddin A, Houranieh A, Zimelman A, Grady T, Mehta P, Behler C, Hayes TG, Efebera YA, Prabhala RH, Han A, Yellapragada SV, Klein CE, Roodman GD, Lichtenstein A, Munshi NC. A phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol. 2015 Apr;169(1):36-43. Epub 2015 Jan 8. Epub 2014 Sep 18. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13243/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25572917 PubMed]
<!-- Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, CA, December 10-13, 2011; and the 55th ASH Annual Meeting and Exposition, New Orleans, LA, December 7-10, 2013. -->
# '''UPFRONT:''' Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. 2015 Nov 20;33(33):3921-9. Epub 2015 Jun 8. [http://jco.ascopubs.org/content/33/33/3921.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26056177 PubMed]

==CPR {{#subobject:6ec39f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CPR: '''<u>C</u>'''yclophosphamide, '''<u>P</u>'''rednisone, '''<u>R</u>'''evlimid (Lenalidomide)

===Regimen {{#subobject:7999a2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.bloodjournal.org/content/127/9/1102.long Magarotto et al. 2016 (EMN01)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#MPR|MPR]]
|style="background-color:#fee08b"|Might have inferior PFS
|-
|2. [[#Rd|Rd]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen is intended for patients who were ineligible for high-dose therapy plus stem cell transplantation because of age (greater than or equal to 65 years) or coexisting comorbidities. This is the dosing used after a mid-protocol amendment.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day on days 1 to 21
*[[Prednisone (Sterapred)]] 25 mg PO once every other day
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

====Supportive medications====
*[[Aspirin]] or [[:Category:Low molecular weight heparins|LMWH]] or [[Warfarin (Coumadin)]] at physician's discretion (mandatory)

'''28-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_monotherapy|Lenalidomide]] versus [[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_.26_Prednisone_2|RP]] maintenance

===References===
# Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016 Mar 3;127(9):1102-8. Epub 2016 Jan 4. [http://www.bloodjournal.org/content/127/9/1102.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26729895 PubMed]

==CTD {{#subobject:658a40|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CTD: '''<u>C</u>'''yclophosphamide, '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone
<br>CTDa: '''<u>C</u>'''yclophosphamide, '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone, '''<u>a</u>'''ttenuated

===Variant #1, CTD {{#subobject:e5fcc6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639680/ Morgan et al. 2010 (MRC Myeloma IX)]
|style="background-color:#1a9851"|Phase III (E)
|[[#CVAD|CVAD]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
''This is an intensive treatment pathway, as determined by performance status, informed discussion, and patient preference.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 500 mg PO once per week
*[[Thalidomide (Thalomid)]] 100 mg PO once per day on days 1 to 21, increasing to 200 mg PO once per day if tolerated
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4, 12 to 15

====Supportive medications====
*Venous thromboembolism (VTE) prophylaxis was given at physician discretion, but it was suggested that low-risk patients receive [[Aspirin]] and high-risk patients receive [[Warfarin (Coumadin)]] or [[:Category:Low_molecular_weight_heparins|low molecular weight heparin]] according to risk categories as described by ''Palumbo A et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–23. [https://www.nature.com/leu/journal/v22/n2/full/2405062a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18094721 PubMed]''
*Patients in the study were randomized to one of the following until progression:
**[[Clodronate (Bonefos)|Sodium clodronate (Bonefos)]] 1600 mg PO once per day 
**[[Zoledronic acid (Zometa)]] 4 mg IV once every 21 to 28 days

'''21-day cycle for 4 to 6 cycles until maximum response'''
====Subsequent treatment====
*Responding patients: [[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan and autologous hematopoietic cell transplant]]

===Variant #2, CTDa {{#subobject:db34fc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639680/ Morgan et al. 2010 (MRC Myeloma IX)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#MP|MP]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
''This is a nonintensive treatment pathway, as determined by performance status, informed discussion, and patient preference.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 500 mg PO once per week
*[[Thalidomide (Thalomid)]] 50 mg PO once per day on days 1 to 28; dose is increased every 4 weeks in 50 mg increments, up to a maximum dose of 200 mg PO once per day 
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1 to 4, 15 to 18

====Supportive medications====
*For the first 12 weeks of treatment, thromboprophylaxis--for example, with [[Warfarin (Coumadin)]] or [[:Category:Low molecular weight heparins|low molecular weight heparin]]--was recommended
*Patients in the study were randomized to a bisphosphonate and received one of the following until progression:
**[[Clodronate (Bonefos)|Sodium clodronate (Bonefos)]] 1600 mg PO once per day 
**[[Zoledronic acid (Zometa)]] 4 mg IV once every 21 to 28 days

'''28-day cycle for 6 to 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Thalidomide_monotherapy|Thalidomide maintenance]] versus [[Multiple_myeloma_-_historical#Observation|no further treatment]]

===References===
# '''MRC Myeloma IX:''' Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010 Dec 11;376(9757):1989-99. Epub 2010 Dec 3. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62051-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639680/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21131037 PubMed]
## '''Update:''' Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Byrne JL, Roddie H, Rudin C, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; NCRI Haematological Oncology Study Group. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011 Aug 4;118(5):1231-8. Epub 2011 Jun 7. [http://www.bloodjournal.org/content/118/5/1231.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152492/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21652683 PubMed]
## '''Update:''' Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012 Jan 5;119(1):7-15. Epub 2011 Oct 20. [http://www.bloodjournal.org/content/119/1/7.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22021371 PubMed]
## '''Update:''' Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012 Mar;97(3):442-50. Epub 2011 Nov 4. [http://www.haematologica.org/content/97/3/442.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291601/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22058209 PubMed]
## '''Update:''' Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson G, Child JA. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013 Nov 1;19(21):6030-8. Epub 2013 Aug 30. [http://clincancerres.aacrjournals.org/content/19/21/6030.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23995858 PubMed]

==CVAD {{#subobject:c3a1db|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CVAD: '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone

===Regimen {{#subobject:51a834|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639680/ Morgan et al. 2010 (MRC Myeloma IX)]
|style="background-color:#1a9851"|Phase III (C)
|[[#CTD|CTD]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
''This is an intensive treatment pathway, as determined by performance status, informed discussion, and patient preference. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 500 mg PO once per day on days 1, 8, 15
*[[Vincristine (Oncovin)]] 0.4 mg/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1.6 mg)
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36 mg/m<sup>2</sup>)
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4, 12 to 15

====Supportive medications====
*Patients in the study were randomized to a bisphosphonate and received one of the following until progression:
**[[Clodronate (Bonefos)|Sodium clodronate (Bonefos)]] 1600 mg PO once per day 
**[[Zoledronic acid (Zometa)]] 4 mg IV once every 21 to 28 days

'''21-day cycle for 4 to 6 cycles until maximum response'''
====Subsequent treatment====
*Responding patients: [[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan and autologous hematopoietic cell transplant]]

===References===
# '''MRC Myeloma IX:''' Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010 Dec 11;376(9757):1989-99. Epub 2010 Dec 3. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62051-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639680/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21131037 PubMed]
## '''Update:''' Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Byrne JL, Roddie H, Rudin C, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; NCRI Haematological Oncology Study Group. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011 Aug 4;118(5):1231-8. Epub 2011 Jun 7. [http://www.bloodjournal.org/content/118/5/1231.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152492/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21652683 PubMed]
## '''Update:''' Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012 Jan 5;119(1):7-15. Epub 2011 Oct 20. [http://www.bloodjournal.org/content/119/1/7.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22021371 PubMed]
## '''Update:''' Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012 Mar;97(3):442-50. Epub 2011 Nov 4. [http://www.haematologica.org/content/97/3/442.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291601/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22058209 PubMed]
## '''Update:''' Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson G, Child JA. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013 Nov 1;19(21):6030-8. Epub 2013 Aug 30. [http://clincancerres.aacrjournals.org/content/19/21/6030.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23995858 PubMed]

==D-VMP {{#subobject:5cbbd5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
D-VMP: '''<u>D</u>'''aratumumab, '''<u>V</u>'''elcade (Bortezomib), '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone
===Regimen {{#subobject:e15b5d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1714678 Mateos et al. 2017 (ALCYONE)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VMP|VMP]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''This regimen was intended for patients with newly diagnosed, documented multiple myeloma who were not eligible for high-dose chemotherapy with stem-cell transplantation owing to coexisting conditions or an age of 65 years or older. Note that dexamethasone is substitute for prednisone on day 1.''
====Chemotherapy====
*[[Daratumumab (Darzalex)]] as follows:
**Cycle 1: 16 mg/kg IV once per day on days 1, 8, 15, 22, 29, 36
**Cycles 2 to 9: 16 mg/kg IV once per day on days 1 & 22
*[[Bortezomib (Velcade)]] as follows:
**Cycle 1: 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11, 22, 25, 29, 32
**Cycles 2 to 9: 1.3 mg/m<sup>2</sup> SC once per day on days 1, 8, 22, 29
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 2 to 4

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg IV or PO once prior to each dose of [[Daratumumab (Darzalex)]]

'''42-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Daratumumab_monotherapy|Daratumumab maintenance]]
===References===
# '''ALCYONE:''' Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018 Feb 8;378(6):518-528. Epub 2017 Dec 12. [https://www.nejm.org/doi/full/10.1056/NEJMoa1714678 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29231133 PubMed]

==MPR {{#subobject:327863|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MPR: '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone, '''<u>R</u>'''evlimid (Lenalidomide)
<br>MPL: '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone, '''<u>L</u>'''enalidomide
===Variant #1, 0.13/1.5/10 {{#subobject:926cbb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.bloodjournal.org/content/127/9/1102.long Magarotto et al. 2016 (EMN01)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#CPR|CPR]]
|style="background-color:#d9ef8b"|Might have superior PFS
|-
|2. [[#Rd|Rd]]
|style="background-color:#d9ef8b"|Might have superior PFS
|-
|}
''This regimen is intended for patients who were ineligible for high-dose therapy plus stem cell transplantation because of age (greater than or equal to 65 years) or coexisting comorbidities. This variant was intended for patients older than 75.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 0.13 mg/kg PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 1.5 mg/kg PO once per day on days 1 to 4 
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 21

====Supportive medications====
*[[Aspirin]] or [[:Category:Low molecular weight heparins|LMWH]] or [[Warfarin (Coumadin)]] at physician's discretion (mandatory)

'''28-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_monotherapy|Lenalidomide]] versus [[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_.26_Prednisone_2|Lenalidomide & Prednisone maintenance]]

===Variant #2, 0.18/1.5/10 {{#subobject:a0c09c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.bloodjournal.org/content/127/9/1102.long Magarotto et al. 2016 (EMN01)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#CPR|CPR]]
|style="background-color:#d9ef8b"|Might have superior PFS
|-
|2. [[#Rd|Rd]]
|style="background-color:#d9ef8b"|Might have superior PFS
|-
|}
''This regimen is intended for patients who were ineligible for high-dose therapy plus stem cell transplantation because of age (greater than or equal to 65 years) or coexisting comorbidities. This variant was intended for patients aged 65 to 75.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 0.18 mg/kg PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 1.5 mg/kg PO once per day on days 1 to 4 
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 21

====Supportive medications====
*[[Aspirin]] or [[:Category:Low molecular weight heparins|LMWH]] or [[Warfarin (Coumadin)]] at physician's discretion (mandatory)

'''28-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_monotherapy|Lenalidomide]] versus [[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_.26_Prednisone_2|Lenalidomide & Prednisone maintenance]]

===Variant #3, 0.18/2/10 {{#subobject:a4f37a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/25/28/4459.long Palumbo et al. 2007]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1112704 Palumbo et al. 2012 (MM-015)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[Multiple_myeloma_-_historical#MP|MP]]
|style="background-color:#1a9850"|Superior PFS
|-
|2. MPR
|style="background-color:#1a9850"|Superior PFS
|-
|[http://www.bloodjournal.org/content/127/9/1109.long Zweegman et al. 2016 (HOVON87/NMSG18)]
|style="background-color:#1a9851"|Phase III (E)
|[[#MPT|MPT-T]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''In '''Palumbo et al. 2007''' this regimen was intended for newly diagnosed multiple myeloma patients greater than or equal to 65 years, or younger if ineligible for high-dose therapy. In '''MM-015''' this regimen was intended for patients with symptomatic, measurable, newly diagnosed multiple myeloma who were not candidates for transplantation (greater than or equal to 65 years of age). In '''HOVON87/NMSG18''' this regimen was intended for patients greater than 65 years of age or patients less than or equal to 65 of age and not eligible for high-dose chemotherapy and peripheral stem cell transplantation with newly diagnosed symptomatic MM.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 0.18 mg/kg PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 2 mg/kg PO once per day on days 1 to 4 
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 21

====Supportive medications====
*'''HOVON87/NMSG18:'''
**[[Aspirin]] 75 or 80 mg PO once per day or [[Carbasalate calcium (Ascal)]] 100 mg PO once per day
***Patients with a history of VTE received [[:Category:Low molecular weight heparins|LMWH]] instead
**[[:Category:Bisphosphonates|Bisphosphonates]] at physician discretion
**Prophylactic antibiotics at physician discretion
*'''MM-015:''' [[Aspirin]] 75 to 100 mg PO once per day as thromboprophylaxis
*'''Palumbo et al. 2007:''' [[Ciprofloxacin (Cipro)]] 500 mg PO twice per day and [[Aspirin]] 100 mg PO once per day

'''28-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_monotherapy|Lenalidomide maintenance]]

===Variant #4, 5/100/10 {{#subobject:eb79d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566809/ Stewart et al. 2015 (ECOG E1A06)]
|style="background-color:#1a9851"|Phase III (E)
|[[#MPT|MPT-T]]
|style="background-color:#eeee01"|Seems to have non-inferior PFS
|-
|}
''This regimen was intended for patients who were greater than or equal to 65 years or were less than 65 years and were not candidates for autologous hematopoietic cell transplantation or had declined transplant.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 5 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 4 
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 21

====Supportive medications====
*[[Aspirin]] was required (dose not specified)
**Full anticoagulation was used for patients at "higher risk" for DVT
*[[Pamidronate (Aredia)]] 90 mg IV once per month recommended for patients with "active bone disease"

'''28-day cycle for 12 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_monotherapy|Lenalidomide maintenance]]

===References===
# Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foà R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT; GIMEMA--Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol. 2007 Oct 1;25(28):4459-65. Epub 2007 Sep 4. [http://jco.ascopubs.org/content/25/28/4459.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17785703 PubMed]
# '''MM-015:''' Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 May 10;366(19):1759-69. Erratum in: N Engl J Med. 2012 Jul 19;367(3):285. [https://www.nejm.org/doi/full/10.1056/NEJMoa1112704 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22571200 PubMed]
# '''ECOG E1A06:''' Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood. 2015 Sep 10;126(11):1294-301. Epub 2015 Jul 8. [http://www.bloodjournal.org/content/126/11/1294.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566809/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26157076 PubMed]
# '''EMN01:''' Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016 Mar 3;127(9):1102-8. Epub 2016 Jan 4. [http://www.bloodjournal.org/content/127/9/1102.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26729895 PubMed]
# '''HOVON87/NMSG18:''' Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukås E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016 Mar 3;127(9):1109-16. Epub 2016 Jan 22. [http://www.bloodjournal.org/content/127/9/1109.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26802176 PubMed]

==MPT {{#subobject:210ba4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MPT: '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone, '''<u>T</u>'''halidomide

===Variant #1, "MPT-T" {{#subobject:d23667|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/127/9/1109.long Zweegman et al. 2016 (HOVON87/NMSG18)]
|style="background-color:#1a9851"|Phase III (C)
|[[#MPR|MPR-R]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen was intended for patients greater than 65 years of age or patients less than or equal to 65 of age and not eligible for high-dose chemotherapy and peripheral stem cell transplantation with newly diagnosed symptomatic MM.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 0.18 mg/kg PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 2 mg/kg PO once per day on days 1 to 4 
*[[Thalidomide (Thalomid)]] 200 mg PO once per day 

====Supportive medications====
*[[Aspirin]] 75 or 80 mg PO once per day or [[carbasalate calcium]] 100 mg PO once per day
**Patients with a history of VTE received [[:Category:Low molecular weight heparins|LMWH]] instead
*[[:Category:Bisphosphonates|Bisphosphonates]] at physician discretion
*Prophylactic antibiotics at physician discretion

'''28-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Thalidomide_monotherapy|Thalidomide maintenance]]

===Variant #2, "MPT-T" {{#subobject:009af3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566809/ Stewart et al. 2015 (ECOG E1A06)]
|style="background-color:#1a9851"|Phase III (C)
|[[#MPR|mPR-R]]
|style="background-color:#eeee01"|Seems to have non-inferior PFS
|-
|}
''This regimen was intended for patients who were greater than or equal to 65 years or were less than 65 years and were not candidates for autologous hematopoietic cell transplantation or had declined transplant.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 4 
*[[Thalidomide (Thalomid)]] 100 mg PO once per day 

====Supportive medications====
*[[Aspirin]] was required (dose not specified)
**Full anticoagulation was used for patients at "higher risk" for DVT
*[[Pamidronate (Aredia)]] 90 mg IV once per month recommended for patients with "active bone disease"

'''28-day cycle for 12 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Thalidomide_monotherapy|Thalidomide maintenance]]

===Variant #3 {{#subobject:5b7e29|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1402551 Benboubker et al. 2014 (FIRST)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Rd|Rd]]
|style="background-color:#d73027"|Inferior OS (*)
|-
|2. [[#Rd|Rd18]]
|style="background-color:#fee08b"|Might have inferior OS
|-
|}
''This regimen was intended for patients who had previously untreated, symptomatic, and measurable multiple myeloma and either were greater than or equal to 65 years of age or were less than 65 years of age and ineligible for stem-cell transplantation. See supplemental appendix for further details of dose reductions from starting dose. Efficacy compared to Rd continuous is based on the 2017 update.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] starting dose as follows:
**Age up to 75 years AND ANC at least 1500/uL AND platelets at least 100 x 10<sup>9</sup>/L: 0.25 mg/kg PO once per day on days 1 to 4
**Older than 75 years AND ANC at least 1500/uL AND platelets at least 100 x 10<sup>9</sup>/L: 0.2 mg/kg PO once per day on days 1 to 4
**Age up to 75 years AND ANC less than 1500/uL but greater than or equal to 1000/uL OR platelets less than 100 x 10<sup>9</sup>/L but greater than or equal to 50 x 10<sup>9</sup>/L: 0.125 mg/kg PO once per day on days 1 to 4
**Older than 75 years AND ANC less than 1500/uL but greater than or equal to 1000/uL OR platelets less than 100 x 10<sup>9</sup>/L but greater than or equal to 50 x 10<sup>9</sup>/L: 0.1 mg/kg PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 2 mg/kg PO once per day on days 1 to 4 
*[[Thalidomide (Thalomid)]] starting dose as follows:
**Age up to 75 years: 200 mg PO once per day
**Older than 75 years: 100 mg PO once per day

'''42-day cycle for 12 cycles'''

===Variant #4 {{#subobject:2b9587|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2010.01524.x/abstract Beksac et al. 2010 (TMSG-2005-001)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#MP|MP]]
|style="background-color:#91cf60"|Seems to have superior ORR
|-
|}
''This regimen was intended for patients with newly diagnosed, untreated, symptomatic, measurable myeloma who were not candidates for high-dose therapy plus stem-cell transplantation because of age (greater than or equal to 65 years) or coexisting conditions.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Thalidomide (Thalomid)]] 100 mg PO once per day 

'''42-day cycle for 9 cycles'''

===Variant #5 {{#subobject:6dc18c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/116/9/1405.long Waage et al. 2010 (NMSG12)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#MP|MP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen was intended for patients with previously untreated symptomatic MM, who were not eligible for high-dose treatment with autologous stem cell support.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 0.25 mg/kg PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 4
*[[Thalidomide (Thalomid)]] as follows:
**Cycle 1: 200 mg PO once per day for one week, then increased to 400 mg PO once per day
**Cycle 2 onwards: 400 mg PO once per day

'''42-day cycles until plateau phase'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Thalidomide_monotherapy|Thalidomide maintenance]]

===Variant #6, "MP-T" {{#subobject:e2f96|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/28/19/3160.long Wijermans et al. 2010 (HOVON 49)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#MP|MP]]
|style="background-color:#d9ef8b"|Might have superior OS
|-
|}
''This regimen was intended for patients with previously untreated MM older than age 65 years.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 0.25 mg/kg PO once per day on days 1 to 5
*[[Prednisone (Sterapred)]] 1 mg/kg PO once per day on days 1 to 5 
*[[Thalidomide (Thalomid)]] 200 mg PO once per day 

====Supportive medications====
*[[:Category:Bisphosphonates|Bisphosphonate]] use recommended with [[Pamidronate (Aredia)]] or [[Clodronate (Bonefos)]]; "a maximum treatment period of 2 years was recommended in patients without active disease."
*During induction therapy, [[:Category:Low_molecular_weight_heparins|low molecular weight heparin]] use recommended with [[Nadroparin (Fraxiparine)]] 2,850 units anti-Xa (for patients greater than 90 kg, dose of 5,700 units anti-Xa)

'''28-day cycle for 8 cycles'''
====Subsequent treatment====
*Thalidomide continues at 200 mg PO once per day for 28 days, then [[Multiple_myeloma,_consolidation_and_maintenance#Thalidomide_monotherapy|thalidomide maintenance]]

===Variant #7 {{#subobject:1474b2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/27/22/3664.long Hulin et al. 2009 (IFM 01/01)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#MP|MP]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''This regimen was intended for patients who had stage II or III newly diagnosed multiple myeloma according to the [[#Durie-Salmon_Staging_System_-_1975|Durie-Salmon criteria]] and were at least 75 years of age. Certain stage I patients were allowed; see text for details.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 0.2 mg/kg PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 2 mg/kg PO once per day on days 1 to 4 
*[[Thalidomide (Thalomid)]] 100 mg PO once per day 

'''42-day cycle for 12 cycles'''

===Variant #8 {{#subobject:6de9f0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan="2"|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961537-2/fulltext Facon et al. 2007 (IFM 99-06)]
|rowspan="2" style="background-color:#1a9851"|Phase III (E)
|1. [[Multiple_myeloma_-_historical#MP|MP]]
|style="background-color:#1a9850"|Superior OS
|-
|2. MEL100
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''This regimen was intended for patients with newly diagnosed multiple myeloma aged 65 to 75 years.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 0.25 mg/kg PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 2 mg/kg PO once per day on days 1 to 4 
*[[Thalidomide (Thalomid)]] 200 mg PO once per day, increased as tolerated after 4 weeks on therapy to maximum dose of 400 mg once per day

'''42-day cycle for 12 cycles'''

===Variant #9 {{#subobject:8813e2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2806%2968338-4/fulltext Palumbo et al. 2006]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#MP|MP]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|}
''This regimen was intended for patients with newly diagnosed multiple myeloma aged 60 to 85 years.''
====Chemotherapy====
*[[Melphalan (Alkeran)]] 4 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 7 
*[[Thalidomide (Thalomid)]] 100 mg PO once per day on days 1 to 28

====Supportive medications====
*[[Enoxaparin (Lovenox)]] 40 mg SC once per day on days 1 to 28 of cycles 1 to 4

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Thalidomide_monotherapy|Thalidomide maintenance]]

===References===
# Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M; Italian Multiple Myeloma Network (GIMEMA). Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006 Mar 11;367(9513):825-31. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2806%2968338-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16530576 PubMed]
## '''Update:''' Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, Montanaro M, Ria R, Capaldi A, Zambello R, Benevolo G, Derudas D, Dore F, Cavallo F, Gay F, Falco P, Ciccone G, Musto P, Cavo M, Boccadoro M. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008 Oct 15;112(8):3107-14. Epub 2008 May 27. [http://www.bloodjournal.org/content/112/8/3107.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18505783 PubMed]
# '''IFM 99-06:''' Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H; Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007 Oct 6;370(9594):1209-18. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961537-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17920916 PubMed] content property of [http://hemonc.org HemOnc.org]
<!-- Presented in part in abstract format at the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2007; XIth International Myeloma Workshop, Kos Island, Greece, June 25-30, 2007; and the American Society of Hematology, Atlanta, GA, December 8-11, 2007. -->
# '''IFM 01/01:''' Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azaïs I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009 Aug 1;27(22):3664-70. Epub 2009 May 18. [http://jco.ascopubs.org/content/27/22/3664.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19451428 PubMed]
# '''NMSG12:''' Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I; Nordic Myeloma Study Group. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010 Sep 2;116(9):1405-12. Epub 2010 May 6. [http://www.bloodjournal.org/content/116/9/1405.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20448107 PubMed]
# '''HOVON 49:''' Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst H, Sonneveld P; Dutch-Belgium Cooperative Group HOVON. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010 Jul 1;28(19):3160-6. Epub 2010 Jun 1. [http://jco.ascopubs.org/content/28/19/3160.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20516439 PubMed]
# '''TMSG-2005-001:''' Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011 Jan;86(1):16-22. Epub 2010 Nov 22. [https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2010.01524.x/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20942865 PubMed]
# '''Meta-analysis:''' Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011 Aug 4;118(5):1239-47. Epub 2011 Jun 13. [http://www.bloodjournal.org/content/118/5/1239.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21670471 PubMed]
# '''FIRST:''' Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 Sep 4;371(10):906-17. [https://www.nejm.org/doi/full/10.1056/NEJMoa1402551 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1402551/suppl_file/nejmoa1402551_appendix.pdf link to supplemental appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25184863 PubMed]
## '''Update:''' Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T. Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol. 2016 Oct;34(30):3609-17. Epub 2016 Jun 20. [http://jco.ascopubs.org/content/34/30/3609.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27325857 PubMed]
## '''Update:''' Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018 Jan 18;131(3):301-310. Epub 2017 Nov 17. [http://www.bloodjournal.org/content/131/3/301.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29150421 PubMed]
# '''ECOG E1A06:''' Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood. 2015 Sep 10;126(11):1294-301. Epub 2015 Jul 8. [http://www.bloodjournal.org/content/126/11/1294.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566809/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26157076 PubMed]
# '''HOVON87/NMSG18:''' Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukås E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016 Mar 3;127(9):1109-16. Epub 2016 Jan 22. [http://www.bloodjournal.org/content/127/9/1109.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26802176 PubMed]

==PAD {{#subobject:955a56|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PAD: '''<u>P</u>'''S-341 (Bortezomib), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone
<br>PAd: '''<u>P</u>'''S-341 (Bortezomib), '''<u>A</u>'''driamycin (Doxorubicin), low-dose '''<u>d</u>'''examethasone
<br>''Note that this regimen is sometimes called VAD but this can create a lot of confusion with the [[Multiple_myeloma_-_historical#VAD|"original" VAD which uses '''<u>V</u>'''incristine]].''
<br>VAD: '''<u>V</u>'''elcade (Bortezomib), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone
<br>BDD: '''<u>B</u>'''ortezomib, '''<u>D</u>'''oxorubicin, '''<u>D</u>'''examethasone
===Variant #1, 1/9/40, IV bortezomib {{#subobject:30a4d0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/30/4635.long Ludwig et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: This is not specifically a first-line regimen but most patients enrolled on the phase II trial were untreated (50 out of 68). The route of bortezomib was not clearly described in the manuscript but has been confirmed with the authors.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
**Patients without grade 3 or 4 toxicity during the first two cycles could have bortezomib dose increased to 1.3 mg/m<sup>2</sup> (route not specified) once per day on days 1, 4, 8, 11
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup> IV once per day on days 1 & 4
**Patients without grade 3 or 4 toxicity during the first two cycles could have number of doxorubicin doses increased to 9 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 40 mg (route not specified) once per day on days 1, 4, 8, 11

'''21-day cycle for up to 8 cycles'''

===Variant #2, 1.3/9/20, SC bortezomib ("PAd") {{#subobject:60f72e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nature.com/leu/journal/v29/n8/full/leu201580a.html Mai et al. 2015 (GMMG-MM5)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VDC|VCD]]
|style="background-color:#eeee01"|Non-inferior VGPR or better rate
|-
|}
''This regimen was intended for patients 18 to 70 years of age with newly diagnosed MM who required systemic chemotherapy based on the CRAB criteria. Note that the bortezomib route was changed from IV to SC with a mid-protocol amendment.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20

====Supportive medications====
*[[Trimethoprim/Sulfamethoxazole_(Bactrim_DS)|Cotrimoxazole]] (dose not specified)
*[[Acyclovir (Zovirax)]] (dose not specified)
*[[:Category:Bisphosphonates|Bisphosphonate]] IV every 4 weeks

'''28-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan & autologous hematopoietic cell transplant]]

===Variant #3, 1.3/9/40 x 3, IV bortezomib {{#subobject:3fc8cd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/24/2946.long Sonneveld et al. 2012 (HOVON-65)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#VAD|VAD]]
|style="background-color:#1a9850"|Superior PFS (*)
|-
|[http://jco.ascopubs.org/content/30/24/2946.long Sonneveld et al. 2012 (GMMG-HD4)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#VAD|VAD]]
|style="background-color:#1a9850"|Superior PFS (*)
|-
|}
''This regimen was intended for patients 18 to 65 years of age with newly diagnosed MM, [[#Durie-Salmon_Staging_System_-_1975|Durie-Salmon stage]] II to III, [[#ECOG_performance_status_.28WHO.2FZubrod_score.29|WHO performance status]] 0 to 2, or WHO 3 when caused by MM. Note that in the initial publication, this arm seemed to have an overall survival advantage; this was no longer present in the updated report of 2017; PFS was the primary endpoint. Stem cells collected 4 to 6 weeks after induction therapy''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20

====Supportive medications====
(described in the appendix of Sonneveld et al. 2012):
*One of the following bisphosphonates recommended:
**[[Pamidronate (Aredia)]] 90 mg IV once every 4 to 6 weeks x at least 2 years
**[[Zoledronic acid (Zometa)]] 4 mg IV once every 4 to 6 weeks x at least 2 years
**[[Ibandronate (Boniva)]] 6 mg IV once every 4 to 6 weeks x at least 2 years
*"Prophylactic antibiotics" (no further specifics) during induction therapy
*Erythropoietin and pain medications at physician discretion
*One of the following for Herpes zoster prophylaxis throughout bortezomib induction:
**[[Acyclovir (Zovirax)]] 800 mg PO per day (did not specify whether taken once per day or as a divided twice per day dose)
**[[Valacyclovir (Valtrex)]] 1000 mg PO per day (did not specify whether taken once per day or as a divided twice per day dose)

'''28-day cycle for 3 cycles'''
====Subsequent treatment====
*HOVON-65: [[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|Single high-dose melphalan & autologous hematopoietic cell transplant]]
*GMMG-HD4: [[Multiple_myeloma,_consolidation_and_maintenance#Tandem_melphalan.2C_then_auto_HSCT|Tandem high-dose melphalan & autologous hematopoietic cell transplant]]

===Variant #4, 1.3/9/40 x 4, IV bortezomib {{#subobject:36a261|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2005.05519.x/full Oakervee et al. 2005]
|style="background-color:#ffffbe"|Phase II, <20 pts (*)
|-
|}
''Note that while this is reported as a phase II, it was also a dose-finding study; only 14 patients were treated at the dose here.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Dexamethasone (Decadron)]] as follows:
**Cycle 1: 40 mg PO once per day on days 1 to 4, 8 to 11, 15 to 18 
**Cycles 2 to 4: 40 mg PO once per day on days 1 to 4

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Stem_cell_mobilization#Cyclophosphamide_.26_G-CSF|Cyclophosphamide stem cell mobilization]], then [[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|high-dose melphalan & autologous hematopoietic cell transplant]]

===References===
# Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2005.05519.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15953001 PubMed]
<!-- Presented in part at the 13th Congress of the European Haematology Association, June 12-15, 2008, Copenhagen, Denmark; the 50th Annual Meeting of the American Society of Hematology, December 6-9, 2008, San Francisco, CA; and the 51st Annual Meeting of the American Society of Hematology, December 5-8, 2009, New Orleans, LA. -->
# Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010 Oct 20;28(30):4635-41. Epub 2010 Sep 7. [http://jco.ascopubs.org/content/28/30/4635.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20823423 PubMed]
# '''HOVON-65/GMMG-HD4:''' Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012 Aug 20;30(24):2946-55. Epub 2012 Jul 16. [http://jco.ascopubs.org/content/30/24/2946.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22802322 PubMed]
## '''Subgroup analysis:''' Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012 Jan 26;119(4):940-8. Epub 2011 Dec 8. [http://www.bloodjournal.org/content/119/4/940.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22160383 PubMed]
## '''Update:''' Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018 Feb;32(2):383-390. Epub 2017 Jul 4. [https://www.nature.com/articles/leu2017211 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28761118 PubMed]
# '''GMMG-MM5:''' Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015 Aug;29(8):1721-9. Epub 2015 Mar 19. [https://www.nature.com/leu/journal/v29/n8/full/leu201580a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25787915 PubMed]
## '''Subgroup analysis:''' Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015 Jul;100(7):964-9. Epub 2015 Apr 3. [http://www.haematologica.org/content/100/7/964.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486231/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25840597 PubMed]

==Rd {{#subobject:cf79ea|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Rd: '''<u>R</u>'''evlimid (Lenalidomide) & low-dose '''<u>d</u>'''examethasone
<br>RevDex: '''<u>Rev</u>'''limid (Lenalidomide) & '''<u>Dex</u>'''amethasone
<br>Ld: '''<u>L</u>'''enalidomide & low-dose '''<u>d</u>'''examethasone
<br>LenDex: '''<u>L</u>'''enalidomide & '''<u>D</u>'''examethasone
===Variant #1, limited duration (4 cycles) {{#subobject:75359c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70284-0/abstract Rajkumar et al. 2009 (ECOG E4A03)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#RD|RD]]
|style="background-color:#1a9850"|Superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956597/ Gay et al. 2010]
|style="background-color:#ffffbe"|Retrospective
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1402888 Palumbo et al. 2014 (GIMEMA RV-MM-PI-209)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00389-7/abstract Gay et al. 2015 (EMN-441)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|}
''In '''ECOG E4A03''' this is the low-dose dexamethasone arm, and was intended for patients with previously untreated symptomatic multiple myeloma, bone marrow plasmacytosis (greater than or equal to 10% plasma cells or sheets of plasma cells) or a biopsy-proven plasmacytoma, and measurable disease defined as serum monoclonal protein more than 1 g/dL and/or urine monoclonal protein greater than or equal to 200 mg/24 h. '''GIMEMA RV-209''' was intended for patients with symptomatic, measurable, newly diagnosed multiple myeloma who were 65 years of age or younger. '''EMN-441''' was intended for transplant-eligible patients with newly diagnosed myeloma aged 65 years or younger.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

====Supportive medications====
(as described in Rajkumar et al. 2009):
*One of the following bisphosphonates:
**[[Pamidronate (Aredia)]] 90 mg IV over 2 to 4 hours once every 4 weeks
**[[Zoledronic acid (Zometa)]] 4 mg IV over 15 minutes once every 4 weeks
*Thromboprophylaxis mandatory (added mid-protocol after excess rates of DVT)

'''28-day cycle for 4 cycles (see below)'''
====Subsequent treatment====
*ECOG E4A03: Responding patients could choose after 4 cycles to proceed to [[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|high-dose melphalan with autologous hematopoietic cell transplant]] or to continue Rd indefinitely
*ECOG E4A03, non-responders: [[Multiple_myeloma,_relapsed/refractory#Thal-Dex|Thal-Dex]] (details not described)
*GIMEMA RV-MM-PI-209: [[Multiple_myeloma,_consolidation_and_maintenance#Tandem_melphalan.2C_then_auto_HSCT|Tandem high-dose melphalan with autologous hematopoietic cell transplant]] versus [[Multiple_myeloma,_consolidation_and_maintenance#MPR_2|MPR consolidation]]
*EMN-441: [[Multiple_myeloma,_consolidation_and_maintenance#Tandem_melphalan.2C_then_auto_HSCT|Tandem high-dose melphalan with autologous hematopoietic cell transplant]] versus CRD consolidation

===Variant #2, limited duration (6 cycles) {{#subobject:6b80b3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31594-X/fulltext Durie et al. 2016 (SWOG S0777)]
|style="background-color:#1a9851"|Phase III (C)
|[[#RVD|VRd]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Rd|Rd maintenance]]

===Variant #3, limited duration (9 cycles) {{#subobject:37a149|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.bloodjournal.org/content/127/9/1102.long Magarotto et al. 2016 (EMN01)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#CPR|CPR]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#MPR|MPR]]
|style="background-color:#fee08b"|Might have inferior PFS
|-
|}
''This regimen is intended for patients who were ineligible for high-dose therapy plus stem cell transplantation because of age (greater than or equal to 65 years) or coexisting comorbidities.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Age 65 to 75 years: 40 mg PO once per day on days 1, 8, 15, 22
**Age greater than 75 years: 20 mg PO once per day on days 1, 8, 15, 22

====Supportive medications====
*One of the following was mandatory:
**[[Aspirin]] or 
**[[:Category:Low molecular weight heparins|LMWH]] or 
**[[Warfarin (Coumadin)]]

'''28-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_monotherapy|Lenalidomide]] versus [[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_.26_Prednisone_2|RP]] maintenance

===Variant #4, limited duration (18 cycles, "Rd18") {{#subobject:cad6e3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1402551 Benboubker et al. 2014 (FIRST)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#MPT|MPT]]
|style="background-color:#1a9850"|Superior OS (*)
|-
|2. Rd continuous
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''This regimen was intended for patients who had previously untreated, symptomatic, and measurable multiple myeloma and either were greater than or equal to 65 years of age or were less than 65 years of age and ineligible for stem-cell transplantation. See supplemental appendix for further details of dose reductions from starting dose. Efficacy based on the 2017 update.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] starting dose as follows:
**Normal renal function: 25 mg PO once per day on days 1 to 21
**Moderate renal impairment (CrCl 30 to 50 mL/min/1.73m<sup>2</sup>): 10 mg PO once per day on days 1 to 21
**Severe renal impairment (CrCl less than 30 mL/min/1.73m<sup>2</sup>): 15 mg PO once every other day on days 1 to 21
*[[Dexamethasone (Decadron)]] starting dose as follows:
**Age less than or equal to 75: 40 mg PO once per day on days 1, 8, 15, 22
**Age greater than 75: 20 mg PO once per day on days 1, 8, 15, 22

'''28-day cycle for 18 cycles'''

===Variant #5, indefinite 28-day cycles {{#subobject:919b70|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1402551 Benboubker et al. 2014 (FIRST)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#MPT|MPT]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|2. Rd18
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''This regimen was intended for patients who had previously untreated, symptomatic, and measurable multiple myeloma and either were greater than or equal to 65 years of age or were less than 65 years of age and ineligible for stem-cell transplantation. See supplemental appendix for further details of dose reductions from starting dose. Efficacy compared to Rd18 based on the 2017 update.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] starting dose as follows:
**Normal renal function: 25 mg PO once per day on days 1 to 21
**Moderate renal impairment (CrCl 30 to 50 mL/min/1.73m<sup>2</sup>): 10 mg PO once per day on days 1 to 21
**Severe renal impairment (CrCl less than 30 mL/min/1.73m<sup>2</sup>): 15 mg PO once every other day on days 1 to 21
*[[Dexamethasone (Decadron)]] starting dose as follows:
**Age up to 75 years: 40 mg PO once per day on days 1, 8, 15, 22
**Older than 75 years: 20 mg PO once per day on days 1, 8, 15, 22

'''28-day cycles'''

===Variant #6, indefinite with 35-day induction cycles {{#subobject:616f4b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031379/ Zonder et al. 2010 (SWOG S0232)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#Dexamethasone_monotherapy|Dexamethasone]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''This regimen was intended for transplantation-ineligible or -denying patients who had to have symptomatic disease with a measurable M-protein, be at least 18 years old, and have a performance status less than 3 (unless resulting from myeloma). Note that the first 3 cycles, termed "induction" in the protocol, were 35-day cycles.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] as follows:
**Cycles 1 to 3: 25 mg PO once per day on days 1 to 28 of a 35-day cycle
**Cycle 4 onwards: 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 3: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20 of a 35-day cycle
**Cycle 4 onwards: 40 mg PO once per day on days 1 to 4

====Supportive medications====
*[[Aspirin]] 325 mg PO once per day unless already on anticoagulation therapy

'''28-day cycles (*)'''

===Variant #7, indefinite 28-day cycles, first 4 with high-dose dex {{#subobject:cb906d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895238/ Rajkumar et al. 2005]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 4: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20 
**Cycle 5 onwards: 40 mg PO once per day on days 1 to 4

====Supportive medications====
*[[Aspirin]] 80 mg or 325 mg (depending on physician choice) PO once per day for thromboprophylaxis

'''28-day cycles'''

===References===
# Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15;106(13):4050-3. Epub 2005 Aug 23. [http://www.bloodjournal.org/content/106/13/4050.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895238/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/16118317 PubMed]
# '''ECOG E4A03:''' Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan;11(1):29-37. Epub 2009 Oct 21. Erratum in: Lancet Oncol. 2010 Jan;11(1):14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70284-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042271/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19853510 PubMed]
## '''Subgroup analysis:''' Jacobus SJ, Kumar S, Uno H, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol. 2011 Nov;155(3):340-8. Epub 2011 Sep 9. [https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2141.2011.08849.x link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192237/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21902684 PubMed]
# '''Retrospective:''' Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010 Sep;85(9):664-9. [http://dx.doi.org/10.1002/ajh.21777 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956597/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20645430 PubMed]
# '''SWOG S0232:''' Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF Sr, Whittenberger BF, Abidi MH, Durie BG, Barlogie B. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010 Dec 23;116(26):5838-41. Epub 2010 Sep 27. [http://www.bloodjournal.org/content/116/26/5838.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031379/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20876454 PubMed]
# Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014 Sep 4;371(10):895-905. [https://www.nejm.org/doi/full/10.1056/NEJMoa1402888 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25184862 PubMed]
# '''FIRST:''' Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 Sep 4;371(10):906-17. [https://www.nejm.org/doi/full/10.1056/NEJMoa1402551 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1402551/suppl_file/nejmoa1402551_appendix.pdf link to supplemental appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25184863 PubMed]
## '''Update:''' Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T. Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol. 2016 Oct;34(30):3609-17. Epub 2016 Jun 20. [http://jco.ascopubs.org/content/34/30/3609.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27325857 PubMed]
## '''Update:''' Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018 Jan 18;131(3):301-310. Epub 2017 Nov 17. [http://www.bloodjournal.org/content/131/3/301.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29150421 PubMed]
# Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1617-29. Epub 2015 Nov 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00389-7/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26596670 PubMed]
# Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016 Mar 3;127(9):1102-8. Epub 2016 Jan 4. [http://www.bloodjournal.org/content/127/9/1102.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26729895 PubMed]
# '''SWOG S0777:''' Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017 Feb 4;389(10068):519-527. Epub 2016 Dec 22. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31594-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28017406 PubMed]

==RVD {{#subobject:97fba9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RVD: '''<u>R</u>'''evlimid (Lenalidomide), '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone
<br>VDR: '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone, '''<u>R</u>'''evlimid (Lenalidomide)
<br>VRD: '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''evlimid (Lenalidomide), '''<u>D</u>'''examethasone
<br>VRd: '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone
===Synopsis===
Induction therapy prior to autologous stem cell transplantation (ASCT) has evolved dramatically from early days, to its current form of lenalidomide, bortezomib, and dexamethasone (RVD). Both [[Multiple_myeloma,_relapsed/refractory#Rd|lenalidomide]] and [[Multiple_myeloma,_relapsed/refractory#Bortezomib_.26_Dexamethasone|bortezomib]], in combination with dexamethasone, demonstrated promising activity in relapsed/refractory multiple myeloma, before being studied in newly-diagnosed patients.<br>
<br>The most relevant studies that have informed clinical practice have demonstrated conclusively that the combination of an immunomodulatory agent (IMiD) and proteasome inhibitor (PI) are most efficacious for disease control and long term outcomes. Intergroup trial SWOG S0777 was a randomized study comparing RVD to Rd for patients with newly diagnosed multiple myeloma, without intention for ASCT ([https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31594-X/fulltext Durie B et al, Lancet 2017 Feb 4]). This trial showed a median progression-free survival (PFS) of 75 months for the RVD arm, as compared with 64 months for the Rd arm. The IFM 2013-04, next, compared outcomes with an IMiD/PI combination induction (bortezomib, thalidomide, dexamethasone – VTD) with the standard at the time, bortezomib, cyclophosphamide and dexamethasone (VCD) ([http://www.bloodjournal.org/content/127/21/2569.long Moreau P et al Blood 2016 May 26]). Responses to VTD were superior to those for VCD, including rates of CR (19% vs 6%), thus establishing the IMiD and PI combination as the preferred induction regimen. As of 2018, we lack randomized data regarding the addition of daratumumab to RVD vs RVD alone, and also whether carfilzomib, lenalidomide, and dexamethasone (KRD) is superior to RVD, though both of these questions are being examined in ongoing clinical trials.<br>
<br>Most variation in this protocol is based on whether it is intended as induction prior to transplant or whether it is part of a transplant-ineligible approach. For the former, 3 cycles are usually given; for the latter, up to 8 cycles are given before transition to maintenance. There is also some variation in how the steroid component is given. To our knowledge, none of the major published trials have used SC bortezomib, although this has been common practice in the clinic since 2010.
===Variant #1, 3 cycles, bi-weekly dexamethasone {{#subobject:45268d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1611750 Attal et al. 2017 (IFM 2009)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''This regimen is intended for patients 65 years of age or younger with symptomatic, measurable, newly diagnosed multiple myeloma.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 14
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan, then auto HSCT]] versus [[Multiple_myeloma,_consolidation_and_maintenance#RVD|RVD consolidation]]

===Variant #2, 3 cycles, weekly dexamethasone {{#subobject:fdbb24|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/32/25/2712.full Roussel et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 14
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15

====Supportive medications====
*[[:Category:Low_molecular_weight_heparins |Low–molecular weight heparin (LMWH)]]
*[[:Category:Antivirals |Antiviral therapy]] with example [[Valacyclovir (Valtrex) | valacyclovir]] given, for herpes zoster prevention
*[[:Category:Antibacterials |Antibiotic prophylaxis]] with example [[Amoxicillin |amoxicillin]] given, for bacterial infections 

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan and autologous hematopoietic cell transplant]]

===Variant #3, 8 cycles, bi-weekly dexamethasone {{#subobject:81b266|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31594-X/fulltext Durie et al. 2016 (SWOG S0777)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Rd|Rd]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''This regimen is intended for patients with previously untreated multiple myeloma who were not planned for immediate autologous stem-cell transplant.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 14
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Rd|Rd maintenance]]
===Variant #4, 8 cycles, weekly dexamethasone {{#subobject:d90d76|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[http://www.bloodjournal.org/content/119/19/4375.long Kumar et al. 2012 (EVOLUTION)]
|rowspan=3 style="background-color:#1a9851"|Randomized Phase II (C)
|1. [[#VDC|VDC]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#VDC|VDC-mod]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#RVDC|VDCR]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen was intended for patients greater than or equal to 18 years of age with previously untreated symptomatic MM, with measurable disease and a [[#Karnofsky_performance_scale|Karnofsky Performance Status]] greater than or equal to 50%, regardless of their eligibility for autologous hematopoietic cell transplantation.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 14
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Bortezomib_monotherapy|Bortezomib consolidation]]

===Variant #5, 8 cycles, tapered bi-weekly dexamethasone {{#subobject:94d215|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324254/ Richardson et al. 2010]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''This is the MTD level "4M" described in the manuscript.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 14
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 4: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
**Cycles 5 to 8: 10 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12

====Supportive medications====
*[[Aspirin]] 81 mg or 325 mg PO once per day 
*[[:Category:Antivirals |Antiviral therapy]], such as [[Acyclovir (Zovirax)]] 400 mg PO once per day 
*[[:Category:Bisphosphonates|Bisphosphonate]]

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*Patients who responded and tolerated therapy could optionally proceed to [[Multiple_myeloma,_consolidation_and_maintenance#RVD|RVD maintenance]]

===References===
# Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 5;116(5):679-86. Epub 2010 Apr 12. [http://www.bloodjournal.org/content/116/5/679.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324254/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20385792 PubMed]
<!-- Presented in abstract form at the 51st American Society of Hematology (ASH) annual meeting, New Orleans, LA, December 7, 2009; the 52nd ASH annual meeting, Orlando, FL, December 6, 2010; and the 13th International Myeloma Workshop, Paris, France, May 5, 2011.-->
# Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012 May 10;119(19):4375-82. Epub 2012 Mar 15. [http://www.bloodjournal.org/content/119/19/4375.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22422823 PubMed]
# Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa AM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien ML, Facon T, Avet-Loiseau H, Attal M. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol. 2014 Sep 1;32(25):2712-7. Epub 2014 Jul 14. [http://jco.ascopubs.org/content/32/25/2712.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25024076 PubMed]
# '''SWOG S0777:''' Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017 Feb 4;389(10068):519-527. Epub 2016 Dec 22. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31594-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28017406 PubMed]
# Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017 Apr 6;376(14):1311-1320. [https://www.nejm.org/doi/full/10.1056/NEJMoa1611750 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28379796 PubMed]

==RVDC {{#subobject:336f84|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RVDC: '''<u>R</u>'''evlimid (Lenalidomide), '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone, '''<u>C</u>'''yclophosphamide
<br>VDCR: '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone, '''<u>C</u>'''yclophosphamide, '''<u>R</u>'''evlimid (Lenalidomide)

===Regimen {{#subobject:78af20|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[http://www.bloodjournal.org/content/119/19/4375.long Kumar et al. 2012 (EVOLUTION)]
|rowspan=3 style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#VDC|VDC]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#VDC|VDC-mod]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#RVD|VDR]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen was intended for patients greater than or equal to 18 years of age with previously untreated symptomatic MM, with measurable disease and a [[#Karnofsky_performance_scale|Karnofsky Performance Status]] greater than or equal to 50%, regardless of their eligibility for autologous hematopoietic cell transplantation.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 14
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8

====Supportive medications====
*[[Aspirin]] 325 mg PO once per day 
**[[Warfarin (Coumadin)]] or [[Enoxaparin (Lovenox)]] could be used based on physician discretion
*[[:Category:PCP_prophylaxis|PCP prophylaxis]] recommended
*[[Acyclovir (Zovirax)]] prophylaxis for Herpes zoster recommended
*[[:Category:Bisphosphonates|Bisphosphonates]] could be used "as necessary"

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Bortezomib_monotherapy|Bortezomib consolidation]]

===References===
<!-- Presented in abstract form at the 51st American Society of Hematology (ASH) annual meeting, New Orleans, LA, December 7, 2009; the 52nd ASH annual meeting, Orlando, FL, December 6, 2010; and the 13th International Myeloma Workshop, Paris, France, May 5, 2011.-->
# Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012 May 10;119(19):4375-82. Epub 2012 Mar 15. [http://www.bloodjournal.org/content/119/19/4375.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22422823 PubMed]

==TAD {{#subobject:b583de|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TAD: '''<u>T</u>'''halidomide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone
===Regimen {{#subobject:42403f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/115/6/1113 Lokhorst et al. 2009 (HOVON-50)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#HOVON-50|See link]]
|style="background-color:#1a9850"|[[Complex_multipart_regimens#HOVON-50|See link]]
|-
|}
====Chemotherapy====
*[[Thalidomide (Thalomid)]] 200 to 400 mg PO once per day
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20

'''28-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Stem_cell_mobilization#CAD_.26_G-CSF|CAD & G-CSF stem-cell mobilization]]

===References===
<!-- Presented in part at the 50th Annual Meeting of the American Society of Hematology, San Francisco, CA, December 7, 2008. -->
# '''HOVON-50:''' Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010 Feb 11;115(6):1113-20. Epub 2009 Oct 30. [http://www.bloodjournal.org/content/115/6/1113 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19880501 PubMed]
## '''Update:''' van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol. 2018 Oct;5(10):e479-e492. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30149-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30290905 PubMed]

==Thal-Dex {{#subobject:13b509|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TD: '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone
<br>Thal-Dex: '''<u>Thal</u>'''idomide, '''<u>Dex</u>'''amethasone
===Variant #1, 50 -> 200 mg/d, 6 cycles {{#subobject:f79d0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.bloodjournal.org/content/120/8/1589.long Rosiñol et al. 2012 (GEM05/MENOS65)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#VTD|VTD]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|2. VBMCP/VBAD/B
|style="background-color:#d3d3d3"|Not reported
|-
|}
''This regimen was intended for patients with newly diagnosed and untreated symptomatic MM who were less than or equal to 65 years of age with measurable serum and/or urine M protein.''
====Chemotherapy====
*[[Thalidomide (Thalomid)]] as follows:
**Cycle 1: 50 mg PO once per day on days 1 to 14, then 100 mg PO once per day on days 15 to 28 
**Cycle 2 onwards: [[Thalidomide (Thalomid)]] 200 mg PO once per day on days 1 to 28
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4, 9 to 12

====Supportive medications====
*[[:Category:Low_molecular_weight_heparins|Low-molecular weight heparin]] or [[Aspirin]] recommended

'''28-day cycle for 6 cycles'''

===Variant #2, 50 -> 200 mg/d, indefinite {{#subobject:d90960|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904367/ Rajkumar et al. 2008]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#Dexamethasone_monotherapy|Dexamethasone]]
|style="background-color:#1a9850"|Superior TTP
|-
|}
''This regimen was intended for patients with previously untreated symptomatic multiple myeloma, bone marrow plasmacytosis (greater than or equal to 10% plasma cells or sheets of plasma cells) or a biopsy-proven plasmacytoma, and measurable disease defined as serum monoclonal protein more than 1 g/dL and/or urine monoclonal protein greater than or equal to 200 mg/24 h.''
====Chemotherapy====
*[[Thalidomide (Thalomid)]] as follows:
**Cycle 1: 50 mg PO once per day on days 1 to 14, then 100 mg PO once per day on days 15 to 28
**Cycle 2 onwards: 200 mg PO once per day on days 1 to 28
*[[Dexamethasone (Decadron)]] as folows:
**Cycles 1 to 4: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20 
**Cycle 5 onwards: 40 mg PO once per day on days 1 to 4

'''28-day cycles'''

===Variant #3, 100 -> 200 mg/d, 3 cycles {{#subobject:437335|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61424-9/fulltext Cavo et al. 2010 (GIMEMA MM-BO2005)]
|style="background-color:#1a9851"|Phase III (C)
|[[#VTD|VTD]]
|style="background-color:#d73027"|Inferior CR/nCR rate
|-
|}
''This regimen was intended for patients aged 18 to 65 years with previously untreated symptomatic myeloma.''
====Chemotherapy====
*[[Thalidomide (Thalomid)]] as follows:
**Cycle 1: 100 mg PO once per day on days 1 to 14, then 200 mg PO once per day on days 15 to 21 
**Cycles 2 & 3: 200 mg PO once per day on days 1 to 21 
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4, 9 to 12

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#Tandem_melphalan.2C_then_auto_HSCT|Tandem MEL200 with auto HSCT]], with interim Thal-Dex maintenance (see paper for details)

===Variant #4, 100 -> 200 mg/d, 4 cycles {{#subobject:bc8d0f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.haematologica.org/content/89/7/826.long Cavo et al. 2004 (Bologna 2002)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Thalidomide (Thalomid)]] as follows:
**Cycle 1: 100 mg PO once per day on days 1 to 14, then 200 mg PO once per day on days 15 to end of month
**Cycles 2 to 4: 200 mg PO once per day on days 1 to end of month 
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 & 3: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
**Cycles 2 & 4: 40 mg PO once per day on days 1 to 4

'''Monthly cycle for 4 cycles'''
====Subsequent treatment====
*Responders: [[Multiple_myeloma,_consolidation_and_maintenance#Tandem_melphalan.2C_then_auto_HSCT|Tandem high-dose melphalan, then autologous hematopoietic cell transplant]].''

===Variant #5, 100 -> 400 mg/day {{#subobject:24c0c5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/21/1/16.full Weber et al. 2003]
|style="background-color:#91cf61"|Phase I/II
|-
|}
====Chemotherapy====
*[[Thalidomide (Thalomid)]] as follows:
**Cycle 1: 100 mg PO once per day on days 1 to 7, then 200 mg PO once per day on days 8 to 14, then 300 mg PO once per day on days 15 to 21, then 400 mg PO once per day on days 22 to 29
**Cycle 2 onwards: 400 mg PO once per day 
*[[Dexamethasone (Decadron)]] 20 mg/m<sup>2</sup> PO once per day on days 1 to 4, 9 to 12, 17 to 20

'''29-day cycles'''

===Variant #6, 200 mg/day {{#subobject:b1c11d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://jco.ascopubs.org/content/20/21/4319.long Rajkumar et al. 2002]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://jco.ascopubs.org/content/24/3/431.long Rajkumar et al. 2005 (ECOG E1A00)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#Dexamethasone_monotherapy|Dexamethasone]]
|style="background-color:#91cf60"|Seems to have superior RR
|style="background-color:#d73027"|Inferior toxicity
|-
|}
''In ECOG E1A00 this regimen was intended for patients with previously untreated symptomatic multiple myeloma, bone marrow plasmacytosis (greater than or equal to 10% plasma cells or sheets of plasma cells) or a biopsy-proven plasmacytoma, and measurable disease defined as serum monoclonal protein more than 1 g/dL and/or urine monoclonal protein greater than or equal to 200 mg/24 h.''
====Chemotherapy====
*[[Thalidomide (Thalomid)]] 200 mg PO once per day on days 1 to 28
*[[Dexamethasone (Decadron)]] as follows:
**Odd-numbered cycles: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
**Even-numbered cycles: 40 mg PO once per day on days 1 to 4

'''28-day cycles'''

===References===
# Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002 Nov 1;20(21):4319-23. [http://jco.ascopubs.org/content/20/21/4319.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12409330 PubMed]
# Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003 Jan 1;21(1):16-9. [http://jco.ascopubs.org/content/21/1/16.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12506164 PubMed]
# '''Bologna 2002:''' Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Testoni N, Tonelli M, de Vivo A, Palareti G, Tura S, Baccarani M. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004 Jul;89(7):826-31. [http://www.haematologica.org/content/89/7/826.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15257934 PubMed]
## '''Sub-analysis:''' Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, de Vivo A, Testoni N, Nicci C, Terragna C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M; Bologna 2002 study. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005 Jul 1;106(1):35-9. Epub 2005 Mar 10. [http://www.bloodjournal.org/content/106/1/35 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15761019 PubMed]
# '''ECOG E1A00:''' Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20;24(3):431-6. Epub 2005 Dec 19. [http://jco.ascopubs.org/content/24/3/431.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16365178 PubMed]
# Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, Olesnyckyj M, Yu Z, Knight R, Zeldis JB, Bladé J. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008 May 1;26(13):2171-7. Epub 2008 Mar 24. [http://jco.ascopubs.org/content/26/13/2171.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904367/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18362366 PubMed]
# '''GIMEMA MM-BO2005:''' Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010 Dec 18;376(9758):2075-85. Epub 2010 Dec 9. Erratum in: Lancet. 2011 Nov 26;378(9806):1846. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61424-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21146205 PubMed]
## '''Update:''' Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012 Jul 5;120(1):9-19. Epub 2012 Apr 12. [http://www.bloodjournal.org/content/120/1/9.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22498745 PubMed]
# '''GEM05/MENOS65:''' Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012 Aug 3;120(8):1589-96. Epub 2012 Jul 12. [http://www.bloodjournal.org/content/120/8/1589.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22791289 PubMed]
## '''Update:''' Rosiñol L, Oriol A, Teruel AI, de la Guía AL, Blanchard M, de la Rubia J, Granell M, Sampol M, Palomera L, González Y, Etxebeste M, Martínez-Martínez R, Hernández MT, de Arriba F, Alegre A, Cibeira M, Mateos M, Martínez-López J, Lahuerta JJ, San Miguel J, Bladé J. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia. 2017 Sep;31(9):1922-1927. Epub 2017 Jan 23. [https://www.nature.com/leu/journal/v31/n9/full/leu201735a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28111466 PubMed]

==VAD doxil {{#subobject:6dfa10|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DVD: '''<u>D</u>'''oxil (Liposomal Doxorubicin), '''<u>V</u>'''incristine, '''<u>D</u>'''examethasone
<br>DVd: '''<u>D</u>'''oxil (Liposomal Doxorubicin), '''<u>V</u>'''incristine, low-dose '''<u>d</u>'''examethasone
<br>VAD doxil: '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin liposomal (Doxil), '''<u>D</u>'''examethasone

===Variant #1, indefinite ("DVd") {{#subobject:72393d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.21662/full Rifkin et al. 2006]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#VAD|VAd]]
|style="background-color:#eeee01"|Non-inferior ORR
|-
|}
''This regimen was intended for patients greater than or equal to 18 years and fulfilling a diagnosis of stage II or III MM according to the [[#Durie-Salmon_Staging_System_-_1975|Durie and Salmon criteria]].''
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 40 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose per cycle capped at 2 mg) IV over 5 minutes once on day 1
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4

'''28-day cycles'''

===Variant #2, limited duration (4 cycles) {{#subobject:f03965|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/14/7/1039.long Dimopoulos et al. 2003]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#VAD|VAD]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://annonc.oxfordjournals.org/content/18/8/1369.long Zervas et al. 2007]
|style="background-color:#1a9851"|Phase III (C)
|TVAD-Doxil
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
'''''Dimopoulos et al. 2003''' was open to all patients with previously untreated multiple myeloma who were considered candidates for systemic treatment. '''Zervas et al. 2007''' was open to patients aged 18 to 75 years old with previously untreated symptomatic MM and a life expectancy of greater than 6 months.''
====Chemotherapy====
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
*[[Pegylated liposomal doxorubicin (Doxil)]] 40 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 & 3: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
**Cycles 2 & 4: 40 mg PO once per day on days 1 to 4

====Supportive medications====
*In the cited Segeren et al. 1999 VAD protocol reference:
*[[Fluconazole (Diflucan)]] 200 mg PO once per day 
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole]] 960 mg (paper did not specify which component was 960 mg) PO twice per day for "prophylaxis"

'''28-day cycle for 4 cycles'''

===Variant #3, limited duration (6 to 8 cycles) {{#subobject:121c56|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.10946/full Hussein et al. 2002]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 40 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
*[[Dexamethasone (Decadron)]] 40 mg IV or PO once per day on days 1 to 4

====Supportive medications====
*Vitamin B6 200 mg PO once per day to help reduce risk of palmar-plantar erythrodysesthesia (PPE)

'''28-day cycle for 6 to 8 cycles'''

===References===
# Hussein MA, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, Bukowski RM. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer. 2002 Nov 15;95(10):2160-8. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.10946/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12412170 PubMed]
# Dimopoulos MA, Pouli A, Zervas K, Grigoraki V, Symeonidis A, Repoussis P, Mitsouli C, Papanastasiou C, Margaritis D, Tokmaktsis A, Katodritou I, Kokkini G, Terpos E, Vyniou N, Tzilianos M, Chatzivassili A, Kyrtsonis MC, Panayiotidis P, Maniatis A; Greek Myeloma Study Group. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol. 2003 Jul;14(7):1039-44. [http://annonc.oxfordjournals.org/content/14/7/1039.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12853344 PubMed]
# Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer. 2006 Feb 15;106(4):848-58. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.21662/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16404741 PubMed]
# Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli CH, Anagnostopoulos A, Delibasi S, Kyrtsonis MC, Anagnostopoulos N, Terpos E, Zikos P, Maniatis A, Dimopoulos MA; Greek Myeloma Study Group. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol. 2007 Aug;18(8):1369-75. [http://annonc.oxfordjournals.org/content/18/8/1369.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17693650 PubMed]

==VAD-P {{#subobject:9671a6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VAD-P: '''<u>Vi</u>'''ncristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone, '''<u>P</u>'''rednisone

===Regimen {{#subobject:1e6b59|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/99/9/3163.long Berenson et al. 2002 (SWOG 9210)]
|style="background-color:#1a9851"|Phase III (C)
|[[#VAD-P.2FQ|VAD-P/Q]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Vincristine (Oncovin)]] 0.4 mg/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1.6 mg)
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36 mg/m<sup>2</sup>)
**Poor-risk patients received 6.75 mg/m<sup>2</sup>/day in cycle 1 (total dose 27 mg/m<sup>2</sup>), with increase to full dose starting cycle 2 if no undue toxicity
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 50 mg PO once per day on days 9, 11, 13, 15, 17, 19

'''21-day cycles for at least 6 months or until at least 25% regression of disease'''
====Subsequent treatment====
*Patients with at least 50% regression in 6 months or 25% regression in 9 to 12 months of therapy: low-dose prednisone versus [[Multiple_myeloma_-_historical#Prednisone_monotherapy|high-dose prednisone]] maintenance

===References===
# '''SWOG 9210:''' Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, Salmon SE. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002 May 1;99(9):3163-8. [http://www.bloodjournal.org/content/99/9/3163.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11964279 PubMed]

==VAD-P/Q {{#subobject:5a391a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VAD-P/Q: '''<u>Vi</u>'''ncristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone, '''<u>P</u>'''rednisone, '''<u>Q</u>'''uinine

===Regimen {{#subobject:9bebf1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/99/9/3163.long Berenson et al. 2002 (SWOG 9210)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VAD-P|VAD-P]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Vincristine (Oncovin)]] 0.4 mg/day IV continuous infusion over 96 hours, started on day 2 (total dose per cycle: 1.6 mg)
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 2 (total dose per cycle: 36 mg/m<sup>2</sup>) 
**Poor-risk patients received 6.75 mg/m<sup>2</sup>/day in cycle 1 (total dose 27 mg/m<sup>2</sup>), with increase to full dose starting cycle 2 if no undue toxicity
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 2 to 5
*[[Prednisone (Sterapred)]] 50 mg PO once per day on days 10, 12, 14, 16, 18, 20
*[[Quinine (Qualaquin)]] 400 mg PO three times per day on days 1 to 6

'''21-day cycle for at least 6 months or until at least 25% regression of disease'''
====Subsequent treatment====
*Patients with at least 50% regression in 6 months or 25% regression in 9 to 12 months of therapy: low-dose prednisone versus [[Multiple_myeloma_-_historical#Prednisone_monotherapy|high-dose prednisone]] maintenance

===References===
# '''SWOG 9210:''' Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, Salmon SE. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002 May 1;99(9):3163-8. [http://www.bloodjournal.org/content/99/9/3163.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11964279 PubMed]

==VDC {{#subobject:f725ee|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VDC: '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone, '''<u>C</u>'''yclophosphamide 
<br>VDC-mod: '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone, '''<u>C</u>'''yclophosphamide ('''<u>mod</u>'''ified dose)
<br>VCD: '''<u>V</u>'''elcade (Bortezomib), '''<u>C</u>'''yclophosphamide, '''<u>D</u>'''examethasone
<br>CyBorD: '''<u>Cy</u>'''clophosphamide, '''<u>Bor</u>'''tezomib, '''<u>D</u>'''examethasone

===Variant #1 {{#subobject:eed411|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/127/21/2569.long Moreau et al. 2016 (IFM 2013-04)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VTD|VTD]]
|style="background-color:#fc8d59"|Seems to have inferior ORR rate
|-
|}
''This regimen was intended for patients aged 65 years or younger with untreated symptomatic MM with measurable paraprotein in serum (greater than 1 g/dL) or urine (greater than 0.2 g/24 hours).''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> PO once per day on days 1, 8, 15
*[[Dexamethasone (Decadron)]] 40 mg (route not specified) once per day on days 1 to 4, 9 to 12

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Autologous hematopoietic cell transplant, with choice of conditioning regimen, whether to perform tandem transplant, and whether to give maintenance at the discretion of the treating center

===Variant #2, "VCD" {{#subobject:5f53d0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nature.com/leu/journal/v29/n8/full/leu201580a.html Mai et al. 2015 (GMMG-MM5)]
|style="background-color:#1a9851"|Phase III (E)
|[[#PAD|PAd]]
|style="background-color:#eeee01"|Non-inferior VGPR or better rate
|-
|}

''This regimen was intended for patients 18 to 70 years of age with newly diagnosed MM who required systemic chemotherapy based on the CRAB criteria. Note that the bortezomib route was changed from IV to SC with a mid-protocol amendment.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
*[[Cyclophosphamide (Cytoxan)]] 900 mg/m<sup>2</sup> IV once on day 1
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12

====Supportive medications====
*[[Trimethoprim/Sulfamethoxazole_(Bactrim_DS)|Cotrimoxazole]] (dose not specified)
*[[Acyclovir (Zovirax)]] (dose not specified)
*[[:Category:Bisphosphonates|Bisphosphonate]] IV every 4 weeks

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan & autologous hematopoietic cell transplant]]

===Variant #3, "VDC" {{#subobject:c78302|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.bloodjournal.org/content/119/19/4375.long Kumar et al. 2012 (EVOLUTION)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (C)
|1. [[#RVD|VDR]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#RVDC|VDCR]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}

''This regimen was intended for patients greater than or equal to 18 years of age with previously untreated symptomatic MM, with measurable disease and a [[#Karnofsky_performance_scale|Karnofsky Performance Status]] greater than or equal to 50%, regardless of their eligibility for autologous hematopoietic cell transplantation. The only difference between this regimen and VDC-mod is the number of cyclophosphamide doses.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8

====Supportive medications====
*[[Aspirin]] 325 mg PO once per day 
**[[Warfarin (Coumadin)]] or [[Enoxaparin (Lovenox)]] could be used based on physician discretion
*[[:Category:PCP_prophylaxis|PCP prophylaxis]] recommended
*[[Acyclovir (Zovirax)]] prophylaxis for Herpes zoster recommended
*[[:Category:Bisphosphonates|Bisphosphonates]] could be used "as necessary"

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Bortezomib_monotherapy|Bortezomib consolidation]]

===Variant #4, "VDC-mod" {{#subobject:a29211|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[http://www.bloodjournal.org/content/119/19/4375.long Kumar et al. 2012 (EVOLUTION)]
|rowspan=3 style="background-color:#91cf61"|Randomized Phase II, less than 20 in this arm (C)
|1. [[#RVD|VDR]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#RVDC|VDCR]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen was intended for patients greater than or equal to 18 years of age with previously untreated symptomatic MM, with measurable disease and a [[#Karnofsky_performance_scale|Karnofsky Performance Status]] greater than or equal to 50%, regardless of their eligibility for autologous hematopoietic cell transplantation. This arm only had 17 patients enrolled; other arms of the EVOLUTION trial all had greater than 20 patients enrolled. The only difference between this and regimen #1 is the number of cyclophosphamide doses.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

====Supportive medications====
*[[Aspirin]] 325 mg PO once per day 
**[[Warfarin (Coumadin)]] or [[Enoxaparin (Lovenox)]] could be used instead, based on physician discretion
*[[:Category:PCP_prophylaxis|PCP prophylaxis]] recommended
*[[Acyclovir (Zovirax)]] prophylaxis for Herpes zoster recommended
*[[:Category:Bisphosphonates|Bisphosphonates]] could be used "as necessary"

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Bortezomib_monotherapy|Bortezomib consolidation]]

===Variant #5, "CyBorD", once per week bortezomib {{#subobject:d82b2d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/115/16/3416.long Reeder et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
''This regimen was described in a letter to the editor of Blood.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> PO once per day on days 1, 8, 15, 22
*[[Bortezomib (Velcade)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 & 2: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20 
**Cycles 3 & 4: 40 mg PO once per week

'''28-day cycle for 4 cycles'''

===Variant #6, "CyBorD" {{#subobject:3f805b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2711213/ Reeder et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> PO once per day on days 1, 8, 15, 22
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20

====Supportive medications====
*[[:Category:Proton pump inhibitors|Proton pump inhibitor (PPI)]]
*[[Acyclovir (Zovirax)]]
*[[:Category:Fluoroquinolone|Quinolone antibiotic]]
*Antifungal mouthwash recommended

'''28-day cycle for 4 to 12 cycles'''

===References===
# Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VH, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009 Jul;23(7):1337-41. Epub 2009 Feb 19. [https://www.nature.com/leu/journal/v23/n7/full/leu200926a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2711213/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19225538 PubMed]
# Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K, Hentz J, Pirooz NA, Piza JG, Tiedemann R, Mikhael JR, Bergsagel PL, Leis JF, Fonseca R, Stewart AK. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010 Apr 22;115(16):3416-7. [http://www.bloodjournal.org/content/115/16/3416.long link to original letter] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20413666 PubMed]
<!-- Presented in abstract form at the 51st American Society of Hematology (ASH) annual meeting, New Orleans, LA, December 7, 2009; the 52nd ASH annual meeting, Orlando, FL, December 6, 2010; and the 13th International Myeloma Workshop, Paris, France, May 5, 2011.-->
# Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012 May 10;119(19):4375-82. Epub 2012 Mar 15. [http://www.bloodjournal.org/content/119/19/4375.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22422823 PubMed]
# '''Meta-Analysis:''' Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, Nagler A, Avigdor A. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Br J Haematol. 2014 Sep;166(5):702-10. Epub 2014 May 26. [http://www.bloodjournal.org/content/119/19/4375.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24861981 PubMed]
# '''GMMG-MM5:''' Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015 Aug;29(8):1721-9. Epub 2015 Mar 19. [https://www.nature.com/leu/journal/v29/n8/full/leu201580a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25787915 PubMed]
## '''Subgroup analysis:''' Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015 Jul;100(7):964-9. Epub 2015 Apr 3. [http://www.haematologica.org/content/100/7/964.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486231/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25840597 PubMed]
# '''IFM2013-04:''' Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016 May 26;127(21):2569-74. Epub 2016 Mar 21. [http://www.bloodjournal.org/content/127/21/2569.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27002117 PubMed]

==VMP {{#subobject:c029ec|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VMP: '''<u>V</u>'''elcade (Bortezomib), '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone
<br>MPV: '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone, '''<u>V</u>'''elcade (Bortezomib)
===Variant #1, 4 cycles {{#subobject:916d56|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/108/7/2165.long Mateos et al. 2006]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''Note: this was the phase II portion of this phase I/II study.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11, 22, 25, 29, 32 
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4

'''42-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#VMP|VMP consolidation]]

===Variant #2, 6 cycles, bi-weekly bortezomib {{#subobject:64da89|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bbmt.org/article/S1083-8791(09)00398-X/abstract Gasparetto et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Melphalan (Alkeran)]] 6 mg/m<sup>2</sup> PO once per day on days 1 to 7, '''given at least 1 hour prior to bortezomib'''
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 7

====Supportive medications====
*[[:Category:Bisphosphonates|Bisphosphonates]] recommended
*[[Acyclovir (Zovirax)]] (dose not specified) recommended

'''28-day cycle for up to 6 cycles'''; treatment could be given beyond 6 cycles at investigator discretion

===Variant #3, 6 cycles, bi-weekly bortezomib x 1, then weekly bortezomib x 5 {{#subobject:48440e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70187-X/fulltext Mateos et al. 2010 (GEM2005)]
|style="background-color:#1a9851"|Phase III (C)
|[[#VTP|VTP]]
|style="background-color:#91cf60"|Seems to have superior OS (*)
|-
|}
''This regimen was intended for patients with untreated multiple myeloma, 65 years and older. Efficacy is based on the 2014 update.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] as follows:
**Cycle 1: 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11, 22, 25, 29, 32 
**Cycles 2 to 5: 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4

====Supportive medications====
*Patients with bone disease received [[:Category:Bisphosphonates|bisphosphonates]]
*Prophylactic [[Acyclovir (Zovirax)|aciclovir]] was recommended.

'''42-day cycle for 1 cycle, then 35-day cycle for 5 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#VP|VP]] versus [[Multiple_myeloma,_consolidation_and_maintenance#VT|VT]] maintenance

===Variant #4, 8 cycles {{#subobject:b06c6b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/33/33/3921.long Niesvizky et al. 2015 (UPFRONT)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Bortezomib_.26_Dexamethasone|VD]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#VTD|VTD]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen was meant for transplant ineligible patients.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4 '''every other cycle'''
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4 '''every other cycle'''

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Bortezomib_monotherapy|Bortezomib consolidation]]

===Variant #5, 9 cycles, bi-weekly bortezomib x 1, then weekly bortezomib x 8 {{#subobject:9994d0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1714678 Mateos et al. 2017 (ALCYONE)]
|style="background-color:#1a9851"|Phase III (C)
|[[#D-VMP|D-VMP]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''This regimen was intended for patients with newly diagnosed, documented multiple myeloma who were not eligible for high-dose chemotherapy with stem-cell transplantation owing to coexisting conditions or an age of 65 years or older.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] as follows:
**Cycle 1: 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11, 22, 25, 29, 32
**Cycles 2 to 9: 1.3 mg/m<sup>2</sup> SC once per day on days 1, 8, 22, 29
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4

'''42-day cycle for 9 cycles'''

===Variant #6, 9 cycles, bi-weekly bortezomib x 4, then weekly bortezomib x 5 {{#subobject:5c31d4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0801479 San Miguel et al. 2008 (VISTA)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#MP|MP]]
|style="background-color:#1a9850"|Superior OS
|-
|[http://jco.ascopubs.org/content/28/34/5101.long Palumbo et al. 2010 (GIMEMA MM-03-05)]
|style="background-color:#1a9851"|Phase III (C)
|[[#VMPT|VMPT-VT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123433/ San-Miguel et al. 2014]
|style="background-color:#1a9851"|Randomized Phase II (C)
|VMP & Siltuximab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''In GIMEMA MM-03-05 and VISTA this regimen was intended for patients with newly diagnosed, untreated, symptomatic, measurable myeloma who were not candidates for high-dose therapy plus stem-cell transplantation because of age (greater than or equal to 65 years) or coexisting conditions.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] as follows:
**Cycles 1 to 4: 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11, 22, 25, 29, 32
**Cycles 5 to 9: 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 8, 22, 29
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4

====Supportive medications====
*[[:Category:Bisphosphonates|Bisphosphonates]] given to patients with myeloma-associated bone disease unless contraindicated (only mentioned in San Miguel et al. 2008)

'''42-day cycle for 9 cycles'''

===Variant #7, 9 cycles, weekly bortezomib {{#subobject:2eb356|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/28/34/5101.long Palumbo et al. 2010 (GIMEMA MM-03-05)]
|style="background-color:#1a9851"|Phase III (C)
|[[#VMPT|VMPT-VT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
''This regimen was intended for patients with newly diagnosed, untreated, symptomatic, measurable myeloma who were not candidates for high-dose therapy plus stem-cell transplantation because of age (greater than or equal to 65 years) or coexisting conditions. This dosing is the result of a mid-protocol amendment.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 8, 15, 22
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4

'''35-day cycle for 9 cycles'''

===References===
# Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006 Oct 1;108(7):2165-72. Epub 2006 Jun 13. [http://www.bloodjournal.org/content/108/7/2165.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16772605 PubMed] 
## '''Update:''' Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008 Apr;93(4):560-5. Epub 2008 Mar 5. [http://www.haematologica.org/content/93/4/560.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18322252 PubMed] 
# '''VISTA:''' San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 Aug 28;359(9):906-17. [https://www.nejm.org/doi/full/10.1056/NEJMoa0801479 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18753647 PubMed]
## '''Update:''' Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010 May 1;28(13):2259-66. Epub 2010 Apr 5. [http://jco.ascopubs.org/content/28/13/2259.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20368561 PubMed] 
## '''Update:''' San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013 Feb 1;31(4):448-55. Epub 2012 Dec 10. [http://jco.ascopubs.org/content/31/4/448.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23233713 PubMed] 
# Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. Epub 2009 Sep 3. [http://www.bbmt.org/article/S1083-8791(09)00398-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19733251 PubMed]
# Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010 Oct;11(10):934-41. Epub 2010 Aug 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70187-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20739218 PubMed]
## '''Subgroup analysis:''' Mateos MV, Gutiérrez NC, Martín-Ramos ML, Paiva B, Montalbán MA, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Martín A, Díaz-Mediavilla J, de Arriba F, Palomera L, Hernández JM, Sureda A, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, Fernández M, García-Sanz R, Vidriales MB, Bladé J, Lahuerta JJ, San Miguel JF. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood. 2011 Oct 27;118(17):4547-53. Epub 2011 Sep 6. [http://www.bloodjournal.org/content/118/17/4547.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21900193 PubMed]
## '''Update:''' Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, López de la Guía A, López J, Bengoechea E, Pérez M, Polo M, Palomera L, de Arriba F, González Y, Hernández JM, Granell M, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Lahuerta JJ, Bladé J, San-Miguel JF. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012 Sep 27;120(13):2581-8. Epub 2012 Aug 13. [http://www.bloodjournal.org/content/120/13/2581 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22889759 PubMed]
## '''Update:''' Mateos MV, Oriol A, Martínez-López J, Teruel AI, López de la Guía A, López J, Bengoechea E, Pérez M, Martínez R, Palomera L, de Arriba F, González Y, Hernández JM, Granell M, Bello JL, Bargay J, Peñalver FJ, Martín-Mateos ML, Paiva B, Montalbán MA, Bladé J, Lahuerta JJ, San-Miguel JF. Update of the GEM2005 trial comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. Blood. 2014 Sep 18;124(12):1887-93. Epub 2014 Aug 7. [http://www.bloodjournal.org/content/124/12/1887 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25102853 PubMed]
# '''GIMEMA MM-03-05:''' Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010 Dec 1;28(34):5101-9. Epub 2010 Oct 12. [http://jco.ascopubs.org/content/28/34/5101.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20940200 PubMed]
## '''Post-hoc analysis:''' Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, Guglielmelli T, Benevolo G, Callea V, Rizzo V, Cangialosi C, Musto P, De Rosa L, Liberati AM, Grasso M, Falcone AP, Evangelista A, Cavo M, Gaidano G, Boccadoro M, Palumbo A. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010 Dec 2;116(23):4745-53. Epub 2010 Aug 31. [http://www.bloodjournal.org/content/116/23/4745.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20807892 PubMed]
## '''Subgroup analysis:''' Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood. 2011 Nov 24;118(22):5759-66. Epub 2011 Sep 27. [http://www.bloodjournal.org/content/118/22/5759.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21951682 PubMed]
## '''Update:''' Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival. J Clin Oncol. 2014 Mar 1;32(7):634-40. Epub 2014 Jan 21. [http://jco.ascopubs.org/content/32/7/634.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24449241 PubMed]
# San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood. 2014 Jun 26;123(26):4136-42. Epub 2014 May 15. Erratum in: Blood. 2014 Aug 14;124(7):1201. [http://www.bloodjournal.org/content/123/26/4136.long link to original article] '''refers to protocol in [https://www.nejm.org/doi/full/10.1056/NEJMoa0801479 San Miguel et al. 2008]''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123433/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24833354 PubMed]
<!-- Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, CA, December 10-13, 2011; and the 55th ASH Annual Meeting and Exposition, New Orleans, LA, December 7-10, 2013. -->
# '''UPFRONT:''' Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. 2015 Nov 20;33(33):3921-9. Epub 2015 Jun 8. [http://jco.ascopubs.org/content/33/33/3921.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26056177 PubMed]
# '''ALCYONE:''' Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018 Feb 8;378(6):518-528. Epub 2017 Dec 12. [https://www.nejm.org/doi/full/10.1056/NEJMoa1714678 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29231133 PubMed]

==VMP, then Rd {{#subobject:adb844|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VMP, then Rd: '''<u>V</u>'''elcade (Bortezomib), '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone, followed by '''<u>R</u>'''evlimid (Lenalidomide), low dose '''<u>d</u>'''examethasone

===Regimen {{#subobject:9bda27|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/127/4/420.long Mateos et al. 2015 (PETHEMA GEM05)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VMP.2FRd|VMP/Rd]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen was intended for patients aged greater than or equal to 65 years with newly diagnosed, untreated, symptomatic, measurable MM.''

====Chemotherapy, VMP portion, first cycle====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11, 22, 25, 29, 32 
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4

'''42-day cycle for 1 cycle, then:'''

====Chemotherapy, VMP portion, remainder====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4

'''28-day cycle for 8 cycles, followed by:'''

====Chemotherapy, Rd portion====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

'''28-day cycle for 9 cycles'''

====Supportive medications====
*During [[Bortezomib (Velcade)|bortezomib]] therapy:
**[[:Category:Bisphosphonates|Bisphosphonates]] 
**[[:Category:Antivirals |Prophylactic antiviral therapy]]
*During [[Lenalidomide (Revlimid)|lenalidomide]] therapy:
**Mandatory thromboprophylaxis with either [[Aspirin]] or [[:Category:Low_molecular_weight_heparins |low–molecular weight heparin]]

===References===
# '''PETHEMA GEM05:''' Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Martín Ramos ML, Oriol A, Bargay J, Bengoechea E, González Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Paiva B, Cedena MT, Puig N, Bladé J, Lahuerta JJ, San-Miguel J. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Blood. 2016 Jan 28;127(4):420-5. Epub 2015 Oct 23. [http://www.bloodjournal.org/content/127/4/420.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26500339 PubMed]

==VMP/Rd {{#subobject:765398|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VMP/Rd: '''<u>V</u>'''elcade (Bortezomib), '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone alternating with '''<u>R</u>'''evlimid (Lenalidomide), low dose '''<u>d</u>'''examethasone

===Regimen {{#subobject:fd772b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/127/4/420.long Mateos et al. 2015 (PETHEMA GEM05)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VMP.2C_then_Rd|VMP, then Rd]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen was intended for patients aged greater than or equal to 65 years with newly diagnosed, untreated, symptomatic, measurable MM.''

====Chemotherapy, VMP portion, first cycle====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11, 22, 25, 29, 32 
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4

'''42-day cycle for 1 cycle, then Rd cycle #1:'''

====Chemotherapy, VMP portion, remaining cycles====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4

'''28-day cycle for 8 cycles, alternating with Rd:'''

====Chemotherapy, Rd portion====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

'''28-day cycle alternating with VMP x 9 cycles'''

====Supportive medications====
*During [[Bortezomib (Velcade)|bortezomib]] therapy:
**[[:Category:Bisphosphonates|Bisphosphonates]] 
**[[:Category:Antivirals |Prophylactic antiviral therapy]]
*During [[Lenalidomide (Revlimid)|lenalidomide]] therapy:
**Mandatory thromboprophylaxis with either [[Aspirin]] or [[:Category:Low_molecular_weight_heparins |low–molecular weight heparin]]

===References===
# Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Martín Ramos ML, Oriol A, Bargay J, Bengoechea E, González Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Paiva B, Cedena MT, Puig N, Bladé J, Lahuerta JJ, San-Miguel J. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Blood. 2016 Jan 28;127(4):420-5. Epub 2015 Oct 23. [http://www.bloodjournal.org/content/127/4/420.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26500339 PubMed]

==VMPT {{#subobject:6b6370|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VMPT: '''<u>V</u>'''elcade (Bortezomib), '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone, '''<u>T</u>'''halidomide

===Variant #1 {{#subobject:cb90b1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/28/34/5101.long Palumbo et al. 2010 (GIMEMA MM-03-05)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VMP|VMP]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''This regimen was intended for patients with newly diagnosed myeloma who were not candidates for high-dose therapy plus stem-cell transplantation because of age (greater than or equal to 65 years) or coexisting comorbidities.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] as follows:
**Cycles 1 to 4: 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11, 22, 25, 29, 32 
**Cycles 5 to 9: 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 8, 22, 29
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Thalidomide (Thalomid)]] 50 mg PO once per day on days 1 to 42

'''42-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#VT|VT maintenance]]

===Variant #2 {{#subobject:5cdd9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/28/34/5101.long Palumbo et al. 2010 (GIMEMA MM-03-05)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VMP|VMP]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''This regimen was intended for patients with newly diagnosed myeloma who were not candidates for high-dose therapy plus stem-cell transplantation because of age (greater than or equal to 65 years) or coexisting comorbidities. This variant represents a mid-protocol change (in 2007) where cycle length was decreased from 6 to 5 weeks and bortezomib was changed to weekly dosing.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 8, 15, 22
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4
*[[Thalidomide (Thalomid)]] 50 mg PO once per day on days 1 to 42

'''35-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#VT|VT maintenance]]

===References===
# '''GIMEMA MM-03-05:''' Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010 Dec 1;28(34):5101-9. Epub 2010 Oct 12. [http://jco.ascopubs.org/content/28/34/5101.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20940200 PubMed]
## '''Post-hoc analysis:''' Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, Guglielmelli T, Benevolo G, Callea V, Rizzo V, Cangialosi C, Musto P, De Rosa L, Liberati AM, Grasso M, Falcone AP, Evangelista A, Cavo M, Gaidano G, Boccadoro M, Palumbo A. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010 Dec 2;116(23):4745-53. Epub 2010 Aug 31. [http://www.bloodjournal.org/content/116/23/4745.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20807892 PubMed]
## '''Subgroup analysis:''' Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood. 2011 Nov 24;118(22):5759-66. Epub 2011 Sep 27. [http://www.bloodjournal.org/content/118/22/5759.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21951682 PubMed]
## '''Update:''' Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014 Mar 1;32(7):634-40. Epub 2014 Jan 21. [http://jco.ascopubs.org/content/32/7/634.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24449241 PubMed]

==VTD {{#subobject:dbab97|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VTD: '''<u>V</u>'''elcade (Bortezomib), '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone
<br>vTD: low-dose '''<u>v</u>'''elcade (Bortezomib), '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone

===Variant #1 {{#subobject:eed411|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/127/21/2569.long Moreau et al. 2016 (IFM 2013-04)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VDC|VCD]]
|style="background-color:#91cf60"|Seems to have superior ORR rate
|-
|}
''This regimen was intended for patients aged 65 years or younger with untreated symptomatic MM with measurable paraprotein in serum (greater than 1 g/dL) or urine (greater than 0.2 g/24 hours).''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
*[[Thalidomide (Thalomid)]] 100 mg PO once per day 
*[[Dexamethasone (Decadron)]] 40 mg (route not specified) once per day on days 1 to 4, 9 to 12

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Autologous hematopoietic cell transplant, with choice of conditioning regimen, whether to perform tandem transplant, and whether to give maintenance at the discretion of the treating center

===Variant #2 {{#subobject:b082c7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/33/33/3921.long Niesvizky et al. 2015 (UPFRONT)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Bortezomib_.26_Dexamethasone|VD]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#VMP|VMP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}

''This regimen was intended for patients with newly diagnosed, symptomatic, measurable MM requiring systemic therapy, and who were ineligible for stem-cell transplantation because of age (greater than or equal to 65 years), comorbidities, or personal preference.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Thalidomide (Thalomid)]] 100 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 4: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
**Cycles 5 to 8: 20 mg PO once per day on days 1, 2, 4, 5

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Bortezomib_monotherapy|Bortezomib consolidation]]

===Variant #3 {{#subobject:6f69a9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/2/247.long Ludwig et al. 2013]
|style="background-color:#1a9851"|Randomized Phase II (C)
|VTDC
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen was intended for patients aged 18 to 70 years with previously untreated, measurable MM requiring systemic therapy, who were candidates for high-dose chemotherapy and autologous hematopoietic cell transplant.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Thalidomide (Thalomid)]] 100 mg PO once per day 
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4, 9 to 12

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Patients who remained eligible for transplant: [[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan with autologous hematopoietic cell transplant]]
*Transplant ineligible patients or patients achieving CR could undergo 4 additional cycles of VTD

===Variant #4 {{#subobject:18f973|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.bloodjournal.org/content/120/8/1589.long Rosiñol et al. 2012 (GEM05/MENOS65)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Thal-Dex|TD]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|2. VBMCP/VBAD/B
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|}
''This regimen was intended for patients with newly diagnosed and untreated symptomatic MM who were 65 years of age or younger with measurable serum and/or urine M protein.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Thalidomide (Thalomid)]] as follows:
**Cycle 1: 50 mg PO once per day on days 1 to 14, then 100 mg PO once per day on days 15 to 28 
**Cycles 2 to 6: 200 mg PO once per day on days 1 to 28
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4, 9 to 12

====Supportive medications====
*[[:Category:Low_molecular_weight_heparins|Low molecular weight heparin (LMWH)]] or [[Aspirin]] recommended

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan autologous hematopoietic cell transplant]]

===Variant #5, "vTD" {{#subobject:788138|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/118/22/5752.full Moreau et al. 2011 (IFM 2007-02)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Bortezomib_.26_Dexamethasone|VD]]
|style="background-color:#1a9850"|Superior VGPR rate
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943328/ Lok et al. 2014]
|style="background-color:#91cf61"|Non-randomized
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|}
'''''IFM 2007-02''' was intended for patients aged 65 years or younger with untreated symptomatic MM with measurable paraprotein in serum (greater than 1 g/dL) or urine (greater than 0.2 g/24 hours). '''Lok et al. 2014''' uses the same dosing except that bortezomib is given SC.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> IV or SC once per day on days 1, 4, 8, 11
*[[Thalidomide (Thalomid)]] 100 mg PO once per day 
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 & 2: 40 mg (route not specified) once per day on days 1 to 4, 9 to 12
**Cycles 3 & 4: 40 mg (route not specified) once per day on days 1 to 4

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan with autologous hematopoietic cell transplant]]

===Variant #6 {{#subobject:ac1b9a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961424-9/fulltext Cavo et al. 2010 (GIMEMA MM-BO2005)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Thal-Dex|TD]]
|style="background-color:#1a9850"|Superior CR/nCR rate
|-
|}
''This regimen was intended for patients aged 18 to 65 years with previously untreated symptomatic myeloma.''

====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Thalidomide (Thalomid)]] as follows:
**Cycle 1: 100 mg PO once per day on days 1 to 14, then 200 mg PO once per day on days 15 to 21 
**Cycles 2 & 3: 200 mg PO once per day on days 1 to 21 
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#Tandem_melphalan.2C_then_auto_HSCT|Tandem MEL200 with auto HSCT]], with interim Thal-Dex maintenance (see paper for details)

===Variant #7 {{#subobject:4901ec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.25143/full Kaufman et al. 2010]
|style="background-color:#ffffbe"|Retrospective
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Thalidomide (Thalomid)]] 100 mg PO once per day 
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4, 9 to 12

====Supportive medications====
*[[Aspirin]] prophylaxis to decrease risk of DVTs
*Prophylactic "treatment with antiviral and antibiotic medications"

'''21-day cycle for 3 to 4 cycles'''

===References===
# '''Retrospective:''' Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer. 2010 Jul 1;116(13):3143-51. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.25143/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20564642 PubMed]
# '''GIMEMA MM-BO2005:''' Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010 Dec 18;376(9758):2075-85. Epub 2010 Dec 9. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961424-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21146205 PubMed]
## '''Update:''' Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012 Jul 5;120(1):9-19. Epub 2012 Apr 12. [http://www.bloodjournal.org/content/120/1/9.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22498745 PubMed]
# '''IFM 2007-02:''' Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011 Nov 24;118(22):5752-8. Epub 2011 Aug 17. [http://www.bloodjournal.org/content/118/22/5752.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21849487 PubMed] 
# '''GEM05/MENOS65:''' Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012 Aug 3;120(8):1589-96. Epub 2012 Jul 12. [http://www.bloodjournal.org/content/120/8/1589.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22791289 PubMed]
## '''Update:''' Rosiñol L, Oriol A, Teruel AI, de la Guía AL, Blanchard M, de la Rubia J, Granell M, Sampol M, Palomera L, González Y, Etxebeste M, Martínez-Martínez R, Hernández MT, de Arriba F, Alegre A, Cibeira M, Mateos M, Martínez-López J, Lahuerta JJ, San Miguel J, Bladé J. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia. 2017 Sep;31(9):1922-1927. Epub 2017 Jan 23. [https://www.nature.com/leu/journal/v31/n9/full/leu201735a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28111466 PubMed]
<!-- Presented in part at the 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, December 5-8, 2009, and the 50th Annual Meeting of the European Hematology Association, Barcelona, Spain, June 10-13, 2010. -->
# Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol. 2013 Jan 10;31(2):247-55. Epub 2012 Oct 22. [http://jco.ascopubs.org/content/31/2/247.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23091109 PubMed]
## '''Update:''' Ludwig H, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Chaturvedi S, Ataman O, Enny C, Feng H, van de Velde H, Viterbo L. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. Br J Haematol. 2015 Nov;171(3):344-54. Epub 2015 Jul 7. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13582/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758383/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26153365 PubMed]
# Lok A, Mocquard J, Bourcier J, Redelsperger L, Bonnet A, Chauvin C, Thomare P, Mahe B, Touzeau C, Moreau P. Subcutaneous Bortezomib incorporated into the Bortezomib-Thalidomide-Dexamethasone regimen as part of frontline therapy in the context of autologous stem-cell transplantation for multiple myeloma. Haematologica. 2014 Mar;99(3):e33-4. Epub 2014 Feb 14. [http://www.haematologica.org/content/99/3/e33.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943328/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24532044 PubMed]
# '''Meta-Analysis:''' Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, Nagler A, Avigdor A. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Br J Haematol. 2014 Sep;166(5):702-10. Epub 2014 May 26. [http://www.bloodjournal.org/content/119/19/4375.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24861981 PubMed]
<!-- Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, CA, December 10-13, 2011; and the 55th ASH Annual Meeting and Exposition, New Orleans, LA, December 7-10, 2013. -->
# '''UPFRONT:''' Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. 2015 Nov 20;33(33):3921-9. Epub 2015 Jun 8. [http://jco.ascopubs.org/content/33/33/3921.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26056177 PubMed]
# '''IFM2013-04:''' Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016 May 26;127(21):2569-74. Epub 2016 Mar 21. [http://www.bloodjournal.org/content/127/21/2569.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27002117 PubMed]

==VTP {{#subobject:56d6fe|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VTP: '''<u>V</u>'''elcade (Bortezomib), '''<u>T</u>'''halidomide, '''<u>P</u>'''rednisone

===Regimen {{#subobject:f707bc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70187-X/fulltext Mateos et al. 2010 (GEM2005)]
|style="background-color:#1a9851"|Phase III (E)
|[[#VMP|VMP]]
|style="background-color:#fc8d59"|Seems to have inferior OS (*)
|-
|}
''This regimen was intended for patients with untreated multiple myeloma, 65 years and older. Efficacy is based on the 2014 update.''
====First cycle====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11, 22, 25, 29, 32 
*[[Thalidomide (Thalomid)]] 50 mg PO once per day on days 1 to 15, then 100 mg PO once per day on days 16 to 42
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4

====Supportive medications====
*Patients with bone disease received [[:Category:Bisphosphonates|bisphosphonates]]
*Prophylactic [[Acyclovir (Zovirax)|aciclovir]] was recommended.
*Thromboprophylaxis with either [[Aspirin]] or [[:Category:Low_molecular_weight_heparins|low-molecular-weight heparin]]

'''42-day cycle for 1 cycle, then'''

====Remainder of induction====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 
*[[Thalidomide (Thalomid)]] 100 mg PO once per day 
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 4

====Supportive medications====
*Patients with bone disease received [[:Category:Bisphosphonates|bisphosphonates]]
*Prophylactic [[Acyclovir (Zovirax)|aciclovir]] was recommended.
*Thromboprophylaxis with either [[Aspirin]] or [[:Category:Low_molecular_weight_heparins|low-molecular-weight heparin]]

'''35-day cycle for 5 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#VP|VP]] versus [[Multiple_myeloma,_consolidation_and_maintenance#VT|VT]] maintenance

===References===
# Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010 Oct;11(10):934-41. Epub 2010 Aug 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70187-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20739218 PubMed]
## '''Subgroup analysis:''' Mateos MV, Gutiérrez NC, Martín-Ramos ML, Paiva B, Montalbán MA, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Martín A, Díaz-Mediavilla J, de Arriba F, Palomera L, Hernández JM, Sureda A, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, Fernández M, García-Sanz R, Vidriales MB, Bladé J, Lahuerta JJ, San Miguel JF. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood. 2011 Oct 27;118(17):4547-53. Epub 2011 Sep 6. [http://www.bloodjournal.org/content/118/17/4547.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21900193 PubMed]
## '''Update:''' Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, López de la Guía A, López J, Bengoechea E, Pérez M, Polo M, Palomera L, de Arriba F, González Y, Hernández JM, Granell M, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Lahuerta JJ, Bladé J, San-Miguel JF. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012 Sep 27;120(13):2581-8. Epub 2012 Aug 13. [http://www.bloodjournal.org/content/120/13/2581 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22889759 PubMed]
## '''Update:''' Mateos MV, Oriol A, Martínez-López J, Teruel AI, López de la Guía A, López J, Bengoechea E, Pérez M, Martínez R, Palomera L, de Arriba F, González Y, Hernández JM, Granell M, Bello JL, Bargay J, Peñalver FJ, Martín-Mateos ML, Paiva B, Montalbán MA, Bladé J, Lahuerta JJ, San-Miguel JF. Update of the GEM2005 trial comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. Blood. 2014 Sep 18;124(12):1887-93. Epub 2014 Aug 7. [http://www.bloodjournal.org/content/124/12/1887 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25102853 PubMed]

==Zoledronic acid therapy {{#subobject:78cd0d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:39fa9f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639680/ Morgan et al. 2010 (MRC Myeloma IX)]
|style="background-color:#1a9851"|Phase III (E)
|Clodronic acid
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Note: this agent was not given as monotherapy, but is included separately from the regimens that it was given with, based on the RCT design.''
====Supportive medications====
*[[Zoledronic acid (Zometa)]] as follows:
**During induction: 4 mg IV over 15 minutes once every 3 to 4 weeks
**Consolidation onwards: 4 mg IV over 15 minutes once every 4 weeks

'''Continued indefinitely'''
===References===
# '''MRC Myeloma IX:''' Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010 Dec 11;376(9757):1989-99. Epub 2010 Dec 3. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62051-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639680/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21131037 PubMed]
## '''Update:''' Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Byrne JL, Roddie H, Rudin C, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; NCRI Haematological Oncology Study Group. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011 Aug 4;118(5):1231-8. Epub 2011 Jun 7. [http://www.bloodjournal.org/content/118/5/1231.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152492/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21652683 PubMed]
## '''Update:''' Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012 Jan 5;119(1):7-15. Epub 2011 Oct 20. [http://www.bloodjournal.org/content/119/1/7.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22021371 PubMed]
## '''Update:''' Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012 Mar;97(3):442-50. Epub 2011 Nov 4. [http://www.haematologica.org/content/97/3/442.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291601/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22058209 PubMed]
## '''Update:''' Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson G, Child JA. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013 Nov 1;19(21):6030-8. Epub 2013 Aug 30. [http://clincancerres.aacrjournals.org/content/19/21/6030.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23995858 PubMed]

=First-line therapy (including transplant ineligible), non-randomized or retrospective data=
''Note: most but not all multiple myeloma first-line regimens specify whether patients are transplant eligible, or not. We will begin to break this section in those respective subsections.''

==BBD {{#subobject:c09648|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BBD: '''<u>B</u>'''endamustine, '''<u>B</u>'''ortezomib, '''<u>D</u>'''examethasone

===Regimen {{#subobject:c9fe76|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.14536/abstract Berdeja et al. 2017]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this is the modified treatment schema.''
====Chemotherapy====
*[[Bendamustine]] 80 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 8, 9, 15, 16

====Supportive medications====
*Mandatory VZV prophylaxis

'''28-day cycle for 8 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Bortezomib_.26_Dexamethasone|Bortezomib & Dexamethasone maintenance]]

===References===
# Berdeja JG, Bauer T, Arrowsmith E, Essell J, Murphy P, Reeves JA Jr, Boccia RV, Donnellan W, Flinn I. Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. Br J Haematol. 2017 Apr;177(2):254-262. Epub 2017 Feb 7. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14536/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28169430 PubMed]

==BiRD {{#subobject:4ea159|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BiRD: '''<u>Bi</u>'''axin, '''<u>R</u>'''evlimid (Lenalidomide), '''<u>D</u>'''examethasone
===Regimen {{#subobject:d718cd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/111/3/1101.long Niesvizky et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Clarithromycin (Biaxin)]] as follows:
**Cycle 1: 500 mg PO twice per day on days 2 to 28 
**Cycle 2 onwards: 500 mg PO twice per day on days 1 to 28
*[[Lenalidomide (Revlimid)]] as follows:
**Cycle 1: 25 mg PO once per day on days 3 to 21 
**Cycle 2 onwards: 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Cycle 1: 40 mg PO once per day on days 1, 2, 3, 8, 15, 22 
**Cycle 2 onwards: 40 mg PO once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Aspirin]] 81 mg PO once per day 
*[[Omeprazole (Prilosec)]] 20 mg PO once per day 
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] PO twice per day, 3 times a week

'''28-day cycles'''

===References===
# Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008 Feb 1;111(3):1101-9. Epub 2007 Nov 7. [http://www.bloodjournal.org/content/111/3/1101.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17989313 PubMed]
## '''Update:''' Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013 Mar 14;121(11):1982-1985. Epub 2013 Jan 8. [http://www.bloodjournal.org/content/121/11/1982.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596960/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23299315 PubMed]
# '''Retrospective:''' Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010 Sep;85(9):664-9. [http://dx.doi.org/10.1002/ajh.21777 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956597/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20645430 PubMed]

==CCyd {{#subobject:a634d0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CCyd: '''<u>C</u>'''arfilzomib, '''<u>Cy</u>'''clophosphamide, '''<u>d</u>'''examethasone
<br>KCyd: '''<u>K</u>'''yprolis (Carfilzomib), '''<u>Cy</u>'''clophosphamide, '''<u>d</u>'''examethasone
===Variant #1, bi-weekly carfilzomib {{#subobject:c2c7b4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/124/1/63 Bringhen et al. 2014 (IST-CAR-506)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV once per day on days 1 & 2 then 36 mg/m<sup>2</sup> IV once per day on days 8, 9, 15, 16
**Cycles 2 to 9: 36 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> PO once per day on days 1, 8, 15
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

'''28-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Carfilzomib_monotherapy|Carfilzomib maintenance]]

===Variant #2, weekly carfilzomib ("wKCyd") {{#subobject:148a16|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/articles/leu2017327 Bringhen et al. 2017 (IST-CAR-561)]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''Note: this is the MTD established for the phase II portion of the trial.''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] 70 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> PO once per day on days 1, 8, 15
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

'''28-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Carfilzomib_monotherapy|Carfilzomib maintenance]]

===References===
<!-- # '''Abstract:''' Palumbo, Antonio; Bringhen, Sara; Villani, Oreste; Siniscalchi, Agostina; Russo, Eleonora; Uccello, Giuseppina; Cerrato, Chiara; Gilestro, Milena; Rossi, Davide; Boccadoro, Mario. Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients. ASH Annual Meeting Abstracts 2012 120: 730 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/730 link to abstract] -->
# '''IST-CAR-506:''' Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedé P, Gentilini F, Ciccone G, Benevolo G, Genuardi M, Montefusco V, Oliva S, Caravita T, Tacchetti P, Boccadoro M, Sonneveld P, Palumbo A. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014 Jul 3;124(1):63-9. Epub 2014 May 22. [http://www.bloodjournal.org/content/124/1/63 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24855212 PubMed]
# '''IST-CAR-561:''' Bringhen S, D'Agostino M, De Paoli L, Montefusco V, Liberati AM, Galieni P, Grammatico S, Muccio VE, Esma F, De Angelis C, Musto P, Ballanti S, Offidani M, Petrucci MT, Gaidano G, Corradini P, Palumbo A, Sonneveld P, Boccadoro M. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia. 2018 Apr;32(4):979-985. Epub 2017 Nov 16. [https://www.nature.com/articles/leu2017327 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29263440 PubMed]

==CMP {{#subobject:95301c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CMP: '''<u>C</u>'''arfilzomib, '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone

===Regimen {{#subobject:f7a7ed|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/125/20/3100.long Moreau et al. 2015]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''This trial was open to patients older than 65 years of age. Although not explicitly stated, this is considered to be a transplant ineligible population in France. The carfilzomib dose of 36 mg/m<sup>2</sup> was considered to be the MTD in this trial.''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV once per day on days 1 & 2, then 36 mg/m<sup>2</sup> IV once per day on days 8, 9, 22, 23, 29, 30
**Cycles 2 to 9: 36 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 22, 23, 29, 30
*[[Melphalan (Alkeran)]] 9 mg/m<sup>2</sup>/day PO on days 1 to 4
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup>/day PO on days 1 to 4

'''42-day cycle for 9 cycles'''

===References===
<!-- Philippe Moreau, MD, PhD1*, Brigitte Kolb2*, Cyrille Hulin, MD3*, Denis Caillot, MD4*, Lotfi Benboubker, MD5*, Mourad Tiab, MD6*, Cyrille Touzeau, MD7*, Xavier Leleu, MD8, Murielle Roussel, MD9*, Carine Chaleteix, MD10*, Michel Attal9 and Thierry Facon, MD. Carfilzomib PLUS Melphalan and Prednisone (CMP) Is A Promising Combination Therapy For The Treatment Of Elderly Patients With NEWLY Diagnosed Multiple Myeloma: Results Of A PHASE I/II Trial In 68 CASES. ASH 2013 Abstract 1933. -->
# Moreau P, Kolb B, Attal M, Caillot D, Benboubker L, Tiab M, Touzeau C, Leleu X, Roussel M, Chaleteix C, Planche L, Chiffoleau A, Fortin J, Avet-Loiseau H, Mary JY, Hulin C, Facon T. Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood. 2015 May 14;125(20):3100-4. Epub 2015 Mar 17. [http://www.bloodjournal.org/content/125/20/3100.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25784682 PubMed]

==CRd (Carfilzomib) {{#subobject:d9be10|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CRd: '''<u>C</u>'''arfilzomib, '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone
<br>KRd: '''<u>K</u>'''yprolis (Carfilzomib), '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone

===Variant #1 {{#subobject:a2dc49|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://oncology.jamanetwork.com/article.aspx?articleid=2363017 Korde et al. 2016 (NCI 11-C-0221)]
|style="background-color:#91cf61"|Phase II
|-
|}
''The minimal difference between this and variant #2 below is the steroid dosing.''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV once per day on days 1, 2, then 36 mg/m<sup>2</sup> IV once per day on days 8, 9, 15, 16
**Cycles 2 to 8: 36 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Cycle 1: 20 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23
**Cycles 2 to 4: 20 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23
**Cycles 5 to 8: 10 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23

'''28-day cycle for 8 cycles'''
====Subsequent treatment====
*Transplant eligible patients underwent stem cell collection after the 4th cycle but were not obligated to proceed to transplant. 
*If transplant was not undertaken, patients proceeded to [[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_monotherapy|lenalidomide maintenance]] after the 8th cycle

===Variant #2 {{#subobject:7401c8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5162553/ Jakubowiak et al. 2012]
|style="background-color:#91cf61"|Phase I/II
|-
|}

''This is the MTD dosing in this phase I/II trial.''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV once per day on days 1, 2, then 36 mg/m<sup>2</sup> IV once per day on days 8, 9, 15, 16
**Cycles 2 to 8: 36 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 4: 40 mg (route not specified) once per day on days 1, 8, 15, 22
**Cycles 1 & 2 at clinician's discretion: 4 mg IV or PO once per day on days 2, 9, 16 (in addition to above)
**Cycles 5 to 8: 20 mg (route not specified) once per day on days 1, 8, 15, 22

'''28-day cycle for 8 cycles'''
====Subsequent treatment====
*Transplant eligible patients underwent stem cell collection after the 4th cycle but were not obligated to proceed to transplant 
*If transplant was not undertaken, patients proceeded to [[Multiple_myeloma,_consolidation_and_maintenance#CRd_.28Carfilzomib.29|CRd maintenance]] after the 8th cycle

===References===
# Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012 Aug 30;120(9):1801-9. Epub 2012 Jun 4. [http://www.bloodjournal.org/content/120/9/1801.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5162553/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22665938 PubMed]
<!--
# '''Abstract:''' Korde, Neha; Zingone, Adriana; Kwok, Mary; Manasanch, Elisabet E.; Costello, Rene; Zuchlinski, Diamond; Mulquin, Marcia; Maric, Irina; Calvo, Katherine R; Braylan, Raul C.; Yuan, Constance; Tembhare, Prashant Ramesh; Stetler-Stevenson, Maryalice; Arthur, Diane C; Raffeld, Mark; Xi, Liqiang; Choyke, Peter; Kurdziel, Karen; Lindenberg, Liza; Steinberg, Seth M.; Roschewski, Mark; Landgren, Ola. Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients ASH Annual Meeting Abstracts 2012 120: 732 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/732 link to abstract] -->
# '''NCI 11-C-0221:''' Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncol. 2015 Sep;1(6):746-54. [http://oncology.jamanetwork.com/article.aspx?articleid=2363017 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26181891 PubMed]

==CRd (Cyclophosphamide) {{#subobject:fdc431|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CRd: '''<u>C</u>'''yclophosphamide, '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone

===Regimen {{#subobject:ccb917|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901994/ Kumar et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> PO once per day on days 1, 8, 15
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Aspirin]] 325 mg PO once per day
*[[:Category:Low_molecular_weight_heparins|LMWH]] or [[Warfarin (Coumadin)]] for patients with history of thrombotic events or at "higher" risk
 
'''28-day cycle for 4 to 12 cycles'''
====Subsequent treatment====
*At physician discretion, patient could proceed to [[Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_monotherapy|lenalidomide maintenance]] +/- dexamethasone, after the 12th cycle, until progression

===References===
# Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, Russell SJ, Mikhael JR, Dingli D, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol. 2011 Aug;86(8):640-5. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901994/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21630308 PubMed]

==CYKLONE {{#subobject:0c91d6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CYKLONE: '''<u>C</u>'''yclophosphamide, '''<u>K</u>'''yprolis (Carfilzomib), Tha'''<u>L</u>'''lidomide, Dexamethas'''<u>ONE</u>'''

===Regimen {{#subobject:cf729e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521972/ Mikhael et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}

''The carfilzomib dose here is the MTD dose, tested in N=29 patients. The authors state that patients could proceed to autologous hematopoietic cell transplant after four cycles but do not provide criteria to undergo transplant as opposed to continuing CYKLONE.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> PO on days 1, 8, 15
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16
**Cycle 2 onwards: 36 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16
*[[Thalidomide (Thalomid)]] 100 mg PO once per day on days 1 to 28
*[[Dexamethasone (Decadron)]] 40 mg PO on days 1, 8, 15, 22

====Supportive medications====
*[[Aspirin]] or [[:Category:Low_molecular_weight_heparins|LMWH]] for patients intolerant of aspirin
*[[Acyclovir (Zovirax)]] 400 mg PO twice per day
*[[:Category:Antibacterials|Antibacterials]] (not further specified)
*250 to 500 ml of IVF prior to cycle 1 doses of [[Carfilzomib (Kyprolis)]] and then only for patients "at risk for tumor lysis syndrome" in subsequent cycles

'''28-day cycle for 4 to 12 cycles (see note)'''
===References===
# Mikhael JR, Reeder CB, Libby EN, Costa LJ, Bergsagel PL, Buadi F, Mayo A, Nagi Reddy SK, Gano K, Dueck AC, Stewart AK. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol. 2015 Apr;169(2):219-27. Epub 2015 Feb 13. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13296/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521972/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25683772 PubMed]

==IRd {{#subobject:74c2a1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
IRd: '''<u>I</u>'''xazomib, '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone
===Regimen {{#subobject:6b49cb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71125-8/abstract Kumar et al. 2014]
|style="background-color:#91cf61"|Phase I/II
|-
|}

''This is the MTD dose of this phase I/II trial.''
====Chemotherapy====
*[[Ixazomib (Ninlaro)]] 4 mg PO once per day on days 1, 8, 15
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

'''28-day cycle for up to 12 cycles''' 
====Subsequent treatment====
*Transplant-eligible patients could proceed to [[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|autologous hematopoietic cell transplant]] after 6 cycles
*Patients who did not undergo transplant proceeded to [[Multiple_myeloma,_consolidation_and_maintenance#Ixazomib_monotherapy|ixazomib maintenance]] after the 12th cycle

===References===
<!-- Presented at ASH 2012 and ASH 2014, Abstract 82: Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results -->
# Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014 Dec;15(13):1503-12. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71125-8/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25456369 PubMed]

==KTd {{#subobject:48ff6b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
KTd: '''<u>K</u>'''yprolis (Carfilzomib), '''<u>T</u>'''halidomide, '''<u>d</u>'''examethasone

===Regimen {{#subobject:d87119|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300390/ Sonneveld et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}

''Three cohorts are reported; optimal dose of carfilzomib is not described.''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV once per day on days 1 & 2, and:
**''Cohort 1:'' 27 mg/m<sup>2</sup> IV once per day on days 8, 9, 15, 16 of cycle 1 and days 1, 2, 8, 9, 15, 16 of subsequent cycles
**''Cohort 2:'' 36 mg/m<sup>2</sup> IV once per day on days 8, 9, 15, 16 of cycle 1 and days 1, 2, 8, 9, 15, 16 of subsequent cycles
**''Cohort 3:'' 45 mg/m<sup>2</sup> IV once per day on days 8, 9, 15, 16 of cycle 1 and days 1, 2, 8, 9, 15, 16 of subsequent cycles
*[[Thalidomide (Thalomid)]] 200 mg PO once per day
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan with stem cell rescue]]

===References===
<!-- # '''Abstract:''' Pieter Sonneveld, Emilie Asselberg-Hacker, Sonja Zweegman, Bronno van der Holt, Marie Jose Kersten, Edo Vellenga, Marinus van Marwijk Kooy, Okke de Weerdt, Sarah Lonergan, Antonio Palumbo, Henk Lokhorst. Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network. Blood Nov 2013,122(21)688 [http://www.bloodjournal.org/content/122/21/688 link to abstract] -->
# Sonneveld P, Asselbergs E, Zweegman S, van der Holt B, Kersten MJ, Vellenga E, van Marwijk-Kooy M, Broyl A, de Weerdt O, Lonergan S, Palumbo A, Lokhorst H. Phase 2 study of carfilzomib, thalidomide and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood. 2015 Jan 15;125(3):449-56. Epub 2014 Nov 14. [http://www.bloodjournal.org/content/125/3/449 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300390/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25398935 PubMed]

==Lenalidomide & Prednisone {{#subobject:583b2a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RP: '''<u>R</u>'''evlimid (Lenalidomide) & '''<u>P</u>'''rednisone
===Regimen {{#subobject:9d35d3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/leu/journal/v27/n3/full/leu2012271a.html Falco et al. 2012]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this is a component of the sequential "RP-MPR-RP" protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Prednisone (Sterapred)]] 50 mg PO three times per week

====Supportive medications====
*[[Aspirin]] 100 mg PO once per day as thromboprophylaxis during [[Lenalidomide (Revlimid)]] treatment. Unclear from protocol if this also means off weeks.
*Antiviral prophylaxis if history of VZV.

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#MPR|MPR consolidation]]

===References===
# Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A, Grasso M, Siez ML, De Paoli L, Oliva S, Molica S, Mina R, Gay F, Benevolo G, Musto P, Omedè P, Freilone R, Bringhen S, Carella AM, Gaidano G, Boccadoro M, Palumbo A. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia. 2013 Mar;27(3):695-701. Epub 2012 Sep 21. [https://www.nature.com/leu/journal/v27/n3/full/leu2012271a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22996335 PubMed]

==PAD doxil {{#subobject:55d959|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PAD doxil: '''<u>P</u>'''S-341 (Bortezomib), liposomal '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone
<br>DVD: '''<u>D</u>'''oxil (Liposomal doxorubicin), '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone
<br>VDD: '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''oxil (Liposomal doxorubicin), '''<u>D</u>'''examethasone
===Variant #1 {{#subobject:57cebe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2011.08884.x/full Berenson et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 5 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 40 mg IV once per day on days 1, 4, 8, 11

'''28-day cycle for up to 8 cycles'''

===Variant #2 {{#subobject:aaa1e3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/5/800.long Palumbo et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Pegylated liposomal doxorubicin (Doxil)]] 30 mg/m<sup>2</sup> IV once on day 4
*[[Dexamethasone (Decadron)]] as follows:
**Cycle 1: 40 mg PO once per day on days 1 to 4, 8 to 11, 15 to 18 
**Cycles 2 to 4: 40 mg PO once per day on days 1 to 4

====Supportive medications====
*[[Acyclovir (Zovirax)]] recommended during [[Bortezomib (Velcade)]] therapy

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Tandem_melphalan.2C_then_auto_HSCT|Tandem MEL-100, then auto HSCT]]

===Variant #3 {{#subobject:e38e22|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/27/30/5015.long Jakubowiak et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Pegylated liposomal doxorubicin (Doxil)]] 30 mg/m<sup>2</sup> IV once on day 4
*[[Dexamethasone (Decadron)]] as follows:
**Cycle 1: 40 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12 
**Cycles 2 to 6: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12

====Supportive medications====
*Low-molecular weight heparin 40 mg SC once per day or [[Aspirin]] 81 mg PO once per day for DVT prophylaxis
*[[Acyclovir (Zovirax)]] 400 mg PO twice per day for Herpes zoster prophylaxis

'''21-day cycle for 6 cycles'''

===References===
# Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, Campagnaro E, Brozo C, Braun T, Talpaz M, Kaminski MS. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol. 2009 Oct 20;27(30):5015-22. Epub 2009 Sep 8. [http://jco.ascopubs.org/content/27/30/5015.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19738129 PubMed]
## '''Update:''' Dytfeld D, Griffith KA, Friedman J, Lebovic D, Harvey C, Kaminski MS, Jakubowiak AJ. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial. Leuk Lymphoma. 2011 Jul;52(7):1271-80. [https://www.tandfonline.com/doi/full/10.3109/10428194.2011.567316 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21699382 PubMed]
# Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol. 2010 Feb 10;28(5):800-7. Epub 2010 Jan 4. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314. [http://jco.ascopubs.org/content/28/5/800.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20048187 PubMed]
## '''Update:''' Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedé P, Montefusco V, Petrucci MT, Giuliani N, Passera R, Pietrantuono G, Boccadoro M, Corradini P, Palumbo A. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood. 2013 Aug 22;122(8):1376-83. Epub 2013 Jun 17. [http://www.bloodjournal.org/content/122/8/1376.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23775712 PubMed]
# Berenson JR, Yellin O, Chen CS, Patel R, Bessudo A, Boccia RV, Yang HH, Vescio R, Yung E, Mapes R, Eades B, Hilger JD, Wirtschafter E, Hilger J, Nassir Y, Swift RA. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol. 2011 Dec;155(5):580-7. Epub 2011 Sep 26. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2011.08884.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21950583 PubMed]

==Total Therapy {{#subobject:06fc58|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:1cd95c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/89/3/789.long Barlogie et al. 1997 (Total Therapy)]
|style="background-color:#91cf61"|Prospective
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa053583 Barlogie et al. 2006 (Total Therapy 2)]
| style="background-color:#1a9851" |Prospective with randomization
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06639.x/full Barlogie et al. 2007 (Total Therapy 3)]
|style="background-color:#91cf61"|Prospective
|-
|}
''Total Therapy is a very complicated regimen, you are highly recommended to refer to the original protocols for further details. Total Therapy 3 is replicated here; the references for Total Therapy 2 are provided below but there are no plans to add this regimen here, for now.''

====Induction therapy, VTD-PACE====
VTD-PACE: '''<u>V</u>'''elcade (Bortezomib), '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone, '''<u>P</u>'''latinum (Cisplatin), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide

*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
*[[Thalidomide (Thalomid)]] 200 mg PO once per day on days 4 to 7
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 4 to 7
*[[Cisplatin (Platinol)]] 10 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 4 (total dose per cycle: 40 mg/m<sup>2</sup>)
*[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 4 (total dose per cycle: 40 mg/m<sup>2</sup>)
*[[Cyclophosphamide (Cytoxan)]] 400 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 4 (total dose per cycle: 1600 mg/m<sup>2</sup>)
*[[Etoposide (Vepesid)]] 40 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 4 (total dose per cycle: 160 mg/m<sup>2</sup>)
*Peripheral blood stem cells (PBSC) are usually collected during cycle 1--cycle 2 PBSC collection is done if needed--with a median CD34 count of 29 x 10<sup>6</sup>/kg. 87% of collections yielded at least 20 x 10<sup>6</sup>/kg.

'''Duration of each cycle not specified; 2 cycles total are given, no more than 8 weeks apart'''

During the interim period between cycle 1 and cycle 2, as well as after cycle 2 and prior to transplant, this is given once platelets have recovered to at least 50 x 10<sup>9</sup>/L:
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1 to 4
*[[Thalidomide (Thalomid)]] 50 mg PO once per day on days 1 to 21

'''21-day cycles, given between induction cycles and transplant'''

In other words, the initial therapy consists of: Induction therapy cycle 1, dexamethasone & thalidomide, induction therapy cycle 2, dexamethasone & thalidomide, then transplant.

====Supportive medications====
*As described in Barlogie et al. 2006, which Barlogie et al. 2007 refers to. Note: Barlogie et al. 2007 lists an incorrect title for the reference. See below for the the correct full reference.
*[[Filgrastim (Neupogen)]] "was administered to support induction and consolidation chemotherapy regimens"
*"Prophylactic antibiotics, histamine H2 blockers, and recombinant erythropoietin" were given as needed
*Low molecular weight heparin (LMWH) prophylaxis was used for all patients receiving thalidomide

====Autologous hematopoietic cell transplant====
''Full details were not provided in Barlogie et al. 2007. Tandem autologous transplants were done between 2 to 6 months apart.
*[[Melphalan (Alkeran)]] 200 mg/m2

During the interim period after transplant 1 and transplant 2, patients receive:
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1 to 4
*[[Thalidomide (Thalomid)]] 50 mg PO once per day on days 1 to 21

'''21-day cycles, given in the time between and after each transplant'''; if platelets less than 50 x 10<sup>9</sup>/L, proceed to year 1 of maintenance therapy. Otherwise, if platelets are at least 50 x 10<sup>9</sup>/L, proceed to consolidation therapy.

====Consolidation chemotherapy, VTD-PACE====
VTD-PACE: '''<u>V</u>'''elcade (Bortezomib), '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone, '''<u>P</u>'''latinum (Cisplatin), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide

''Cycle 1 of consolidation starts 1.5 to 4 months after the last transplant. Cycle 2 of consolidation starts 2 to 4 months after cycle 1 of consolidation.''
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
*[[Thalidomide (Thalomid)]] 200 mg PO once per day on days 1 to 4
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4
*[[Cisplatin (Platinol)]] 7.5 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 30 mg/m<sup>2</sup>)
*[[Doxorubicin (Adriamycin)]] 7.5 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 30 mg/m<sup>2</sup>)
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1200 mg/m<sup>2</sup>)
*[[Etoposide (Vepesid)]] 30 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 120 mg/m<sup>2</sup>)

'''2 cycles total are given according to the interval specified above, with the interim therapy below used'''

During the interim period between cycle 1 and cycle 2, as well as after cycle 2 and prior to maintenance therapy, this is given once platelets have recovered to at least 50 x 10<sup>9</sup>/L:
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1 to 4
*[[Thalidomide (Thalomid)]] 100 mg PO once per day on days 1 to 21

'''21-day cycles, given between consolidation cycles and maintenance'''

In other words, consolidation therapy consists of: Consolidation therapy cycle 1, dexamethasone & thalidomide, consolidation therapy cycle 2, dexamethasone & thalidomide, then maintenance therapy.

====Supportive medications====
*As described in Barlogie et al. 2006, which Barlogie et al. 2007 refers to. Note: Barlogie et al. 2007 lists an incorrect title for the reference. See below for the the correct full reference.
*[[Filgrastim (Neupogen)]] "was administered to support induction and consolidation chemotherapy regimens"
*"Prophylactic antibiotics, histamine H2 blockers, and recombinant erythropoietin" were given as needed
*Low molecular weight heparin (LMWH) prophylaxis was used for all patients receiving thalidomide

====Maintenance chemotherapy, year 1 - VTD====
VTD: '''<u>V</u>'''elcade (Bortezomib), '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone

''Year 1 of maintenance therapy starts 1 to 4 months after consolidation cycle 2.''
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
*[[Thalidomide (Thalomid)]] 100 mg PO once per day on days 1 to 28
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1 to 4, 8 to 11

'''28-day cycle for 1 year''', then proceed to maintenance therapy years 2 to 3

====Maintenance chemotherapy, years 2 & 3 - TD====
TD: '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone

*[[Thalidomide (Thalomid)]] 100 mg PO once every other day
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1 to 4

'''28-day cycle for 2 years'''

===References===
# '''Total Therapy:''' Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997 Feb 1;89(3):789-93. [http://www.bloodjournal.org/content/89/3/789.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9028309 PubMed]
## '''Update:''' Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999 Jan 1;93(1):55-65. [http://www.bloodjournal.org/content/93/1/55.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9864146 PubMed]
## '''Pooled update:''' Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. [http://jco.ascopubs.org/content/28/7/1209.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834471/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20085933 PubMed]
# '''Total Therapy 2:''' Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 9;354(10):1021-30. [https://www.nejm.org/doi/full/10.1056/NEJMoa053583 link to original article] '''supportive medication details''' [https://www.ncbi.nlm.nih.gov/pubmed/16525139 PubMed]
## '''Update:''' Zangari M, van Rhee F, Anaissie E, Pineda-Roman M, Haessler J, Crowley J, Barlogie B. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of Total Therapy 1. Br J Haematol. 2008 May;141(4):433-44. Epub 2008 Mar 26. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.06982.x/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649864/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18371114 PubMed]
## '''Subgroup analysis:''' Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008 Oct 15;112(8):3115-21. Epub 2008 May 20. [http://www.bloodjournal.org/content/112/8/3115.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569166/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18492953 PubMed]
## '''Pooled update:''' Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. [http://jco.ascopubs.org/content/28/7/1209.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834471/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20085933 PubMed]
# '''Total Therapy 3:''' Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD Jr. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of Total Therapy 3. Br J Haematol. 2007 Jul;138(2):176-85. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06639.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17593024 PubMed]
## '''Update:''' Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy JD Jr, Barlogie B. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008 Mar;140(6):625-34. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06921.x/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655432/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18302711 PubMed]
## '''Pooled update:''' Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. [http://jco.ascopubs.org/content/28/7/1209.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834471/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20085933 PubMed]

==VP {{#subobject:8cd2dc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VP: '''<u>V</u>'''elcade (Bortezomib) & '''<u>P</u>'''rednisone
===Regimen {{#subobject:19553c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/leu/journal/v30/n6/full/leu201636a.html Larocca et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 8, 15, 22
*[[Prednisone (Sterapred)]] 50 mg PO once every other day

'''28-day cycle for 9 cycles'''
====Subsequent treatment====
*[[Multiple_myeloma,_consolidation_and_maintenance#Bortezomib_monotherapy_2|Bortezomib maintenance]]

===References===
# Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Montefusco V, Passera R, De Rosa L, Omedé P, Vincelli ID, Spada S, Carella AM, Ponticelli E, Derudas D, Genuardi M, Guglielmelli T, Nozzoli C, Aghemo E, De Paoli L, Conticello C, Musolino C, Offidani M, Boccadoro M, Sonneveld P, Palumbo A. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. Leukemia. 2016 Jun;30(6):1320-6. [https://www.nature.com/leu/journal/v30/n6/full/leu201636a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26898189 PubMed]

==VTD-PACE {{#subobject:539ce9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VTD-PACE: '''<u>V</u>'''elcade (Bortezomib), '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone, '''<u>P</u>'''latinum (Cisplatin), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide

===Regimen {{#subobject:b0b58e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06639.x/full Barlogie et al. 2007 (Total Therapy 3)]
|style="background-color:#91cf61"|Prospective
|-
|}

''Note: this is the induction therapy used in Total Therapy 3. We are not aware of other sources prospectively describing VTD-PACE.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
*[[Thalidomide (Thalomid)]] 200 mg PO once per day on days 4 to 7
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 4 to 7
*[[Cisplatin (Platinol)]] 10 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 4 (total dose per cycle: 40 mg/m<sup>2</sup>)
*[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 4 (total dose per cycle: 40 mg/m<sup>2</sup>)
*[[Cyclophosphamide (Cytoxan)]] 400 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 4 (total dose per cycle: 1600 mg/m<sup>2</sup>)
*[[Etoposide (Vepesid)]] 40 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 4 (total dose per cycle: 160 mg/m<sup>2</sup>)

'''Duration of each cycle not specified; 2 cycles total are given, no more than 8 weeks apart'''

===References===
# '''Total Therapy 3:''' Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD Jr. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of Total Therapy 3. Br J Haematol. 2007 Jul;138(2):176-85. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06639.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17593024 PubMed]
<section end=1st-line />
{{#lst:Multiple myeloma|bottom}}
[[Category:Multiple myeloma regimens]]
[[Category:Disease-specific pages]]
[[Category:Plasma cell dyscrasias]]
